[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 392
6. Pocard M, Sabourin JC: [Not Available]. J Chir (Paris); 2008 Dec;145S4:12S17-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sabourin In theory, the concept of sentinel lymph node (SLN) biopsy can be applied to cancer surgery for all solid cancers.
  • Yet sentinel lymph node biopsy has not become a standard part of gastrointestinal cancer surgery.
  • Studies of SLN biopsy in colon cancer have not shown it to be a reliable predictor of N+ status and therefore don't permit the omission of lymph node dissection in selected cases.
  • SLN biopsy may have prognostic usefulness by demonstrating micrometastases; careful serial sectioning focussed on the SLN may detect nests of metastatic cells on HE staining, thereby converting a tumor from Stage I (TxN0M0) to Stage II (TxN1M0).
  • For cancers of the anal canal, SLN biopsy of inguinal nodes has been tested as a means of establishing the indications for inguinal lymph node dissection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Masson SAS. All rights reserved.
  • (PMID = 22793980.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


7. Minicozzi A, Borzellino G, Momo R, Steccanella F, Pitoni F, de Manzoni G: Perianal Paget's disease: presentation of six cases and literature review. Int J Colorectal Dis; 2010 Jan;25(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In three cases, the disease recurred locally, but no patient developed metastatic spread.
  • The Paget's disease can relapse after radical surgery and has a capacity of metastatic spread.
  • [MeSH-major] Anal Canal / pathology. Paget Disease, Extramammary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Dermatol. 2005 May-Jun;15(3):168-70 [15908300.001]
  • [Cites] Am J Dermatopathol. 1992 Oct;14(5):402-7 [1384380.001]
  • [Cites] Int J Colorectal Dis. 2008 Nov;23(11):1125-30 [18535830.001]
  • [Cites] Histopathology. 1997 Oct;31(4):384-5 [9363457.001]
  • [Cites] Histopathology. 2002 Aug;41(2):177-9 [12147102.001]
  • [Cites] Am Surg. 2007 Mar;73(3):307-9 [17375797.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Eur J Surg Oncol. 1993 Oct;19(5):469-73 [8405484.001]
  • [Cites] J R Soc Med. 1991 Feb;84(2):112-3 [1847974.001]
  • [Cites] South Med J. 2000 Jul;93(7):713-5 [10923963.001]
  • [Cites] Dis Colon Rectum. 2000 Apr;43(4):499-502 [10789745.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2002 Aug;14(4):272-84 [12206637.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 May;21(5):581-90 [17447970.001]
  • [Cites] Br J Dermatol. 2006 Feb;154(2):375-6 [16433815.001]
  • [Cites] Am J Surg. 2001 Apr;181(4):363-5 [11438274.001]
  • [Cites] Acta Pathol Jpn. 1991 May;41(5):386-93 [1651042.001]
  • [Cites] J Am Acad Dermatol. 2004 Nov;51(5):767-73 [15523356.001]
  • [Cites] Int J Colorectal Dis. 1992 Sep;7(3):167-9 [1328429.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):170-9 [9500217.001]
  • [Cites] Am J Dermatopathol. 1996 Apr;18(2):118-23 [8739985.001]
  • [Cites] Br J Plast Surg. 1999 Sep;52(6):471-5 [10673924.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;24(1):73-8 [1324902.001]
  • [Cites] BJOG. 2005 Mar;112(3):273-9 [15713139.001]
  • [Cites] Surg Today. 1996;26(9):711-4 [8883244.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1469-77 [11717535.001]
  • [Cites] Gastroenterol Jpn. 1993 Oct;28(5):719-24 [8224624.001]
  • [Cites] Dermatol Surg. 2003 Jul;29(7):723-7 [12828695.001]
  • [Cites] Pathol Int. 2004 Aug;54(8):630-5 [15260855.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1077-81 [9870855.001]
  • [Cites] Surg Today. 2006;36(7):666-9 [16794808.001]
  • [Cites] Eur J Surg Oncol. 2000 Sep;26(6):612-4 [11034816.001]
  • [Cites] J Cutan Pathol. 2002 Mar;29(3):185-9 [11972718.001]
  • [Cites] Dermatol Surg. 1997 Nov;23(11):1032-4 [9391559.001]
  • [Cites] Dis Colon Rectum. 1990 Jun;33(6):502-7 [2161727.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1563-5 [14605581.001]
  • [Cites] Am J Gastroenterol. 1990 Feb;85(2):199-202 [2154090.001]
  • [Cites] Br J Dermatol. 2000 Jan;142(1):59-65 [10651695.001]
  • [Cites] J Dermatolog Treat. 2006;17 (3):167-71 [16854759.001]
  • [Cites] Acta Gastroenterol Belg. 2004 Apr-Jun;67(2):228-31 [15285581.001]
  • [Cites] Br J Radiol. 1999 Jun;72(858):610-2 [10560346.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):933-8 [1846769.001]
  • [Cites] Jpn J Clin Oncol. 1998 May;28(5):347-50 [9703865.001]
  • [Cites] Dermatol Surg. 2003 Jan;29(1):21-4 [12534507.001]
  • [Cites] J Dermatol. 2005 Aug;32(8):632-7 [16334862.001]
  • [Cites] Int J Colorectal Dis. 2005 Mar;20(2):199-200 [15449079.001]
  • [Cites] J R Soc Med. 2001 Mar;94(3):137-8 [11285798.001]
  • [Cites] Mod Pathol. 2006 Feb;19 Suppl 2:S93-S126 [16446719.001]
  • [Cites] Med Sci Monit. 2007 Jun;13(6):CS75-7 [17534239.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 Apr;22(4):522-3 [18363931.001]
  • [Cites] Dis Colon Rectum. 2001 Jun;44(6):868-70 [11391150.001]
  • [Cites] Dermatology. 2005;210(4):315-8 [15942218.001]
  • [Cites] Ann Surg Oncol. 1997 Sep;4(6):475-80 [9309336.001]
  • [Cites] Eur J Dermatol. 2003 Jan-Feb;13(1):93-4 [12609793.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):150-2 [2153511.001]
  • [Cites] Am J Surg. 2004 Mar;187(3):413-6 [15006574.001]
  • [Cites] J Cutan Med Surg. 2006 Jul-Aug;10(4):197-200 [17234119.001]
  • [Cites] Br J Dermatol. 1999 Nov;141(5):951-3 [10583201.001]
  • [Cites] Dis Colon Rectum. 1996 Feb;39(2):227-31 [8620793.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2007;60(11):1208-13 [17409038.001]
  • [Cites] J Am Coll Surg. 2003 Jan;196(1):45-50 [12517548.001]
  • [Cites] Colorectal Dis. 2004 May;6(3):206-9 [15109389.001]
  • [Cites] Pathology. 1998 Feb;30(1):1-3 [9534198.001]
  • [Cites] Ann R Coll Surg Engl. 2004 Nov;86(6):W26-31 [16749961.001]
  • [Cites] Cancer. 1992 Apr 15;69(8):2166-71 [1311986.001]
  • [Cites] G Chir. 2008 Nov-Dec;29(11-12):469-74 [19068182.001]
  • [Cites] Dermatol Surg. 2004 Oct;30(10 ):1329-34 [15458530.001]
  • (PMID = 19707774.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 67
  •  go-up   go-down


8. Wang Y, Ao X, Vuong H, Konanur M, Miller FR, Goodison S, Lubman DM: Membrane glycoproteins associated with breast tumor cell progression identified by a lectin affinity approach. J Proteome Res; 2008 Oct;7(10):4313-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the distribution of glycoprotein expression as a function of MW and p I was very similar between the two related cell lines tested, the approach enabled the identification of several distinct membrane glycoproteins with an expression index correlated with either a precancerous (MCF10AT1), or a malignant, metastatic cellular phenotype (MCF10CA1a).
  • Among the proteins associated with the malignant phenotype, Gamma-glutamyl hydrolase, CD44, Galectin-3-binding protein, and Syndecan-1 protein have been reported as potential biomarkers of breast cancer.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jul;6(3):287-97 [11547898.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):26967-75 [10871609.001]
  • [Cites] Tumour Biol. 2001 Nov-Dec;22(6):348-66 [11786729.001]
  • [Cites] FEBS Lett. 2002 Apr 10;516(1-3):217-24 [11959136.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Glycobiology. 2003 Jun;13(6):457-70 [12626390.001]
  • [Cites] Proteomics. 2003 Jul;3(7):1256-69 [12872226.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):796-801 [12920224.001]
  • [Cites] J Proteome Res. 2003 Sep-Oct;2(5):543-52 [14582651.001]
  • [Cites] Proteomics. 2004 Mar;4(3):562-77 [14997480.001]
  • [Cites] Anal Chem. 2004 Apr 1;76(7):1817-23 [15053638.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] J Invest Dermatol. 2004 Oct;123(4):691-9 [15373774.001]
  • [Cites] Hum Pathol. 2004 Oct;35(10):1196-209 [15492986.001]
  • [Cites] Biochim Biophys Acta. 1979 Dec 20;559(4):329-76 [391282.001]
  • [Cites] J Biol Chem. 1985 Jun 10;260(11):6882-7 [3997852.001]
  • [Cites] Cancer Res. 1986 Jun;46(6):3005-10 [3516389.001]
  • [Cites] Br J Cancer. 1987 Mar;55(3):249-54 [2436644.001]
  • [Cites] Am J Clin Nutr. 1987 Aug;46(2):295-301 [3039825.001]
  • [Cites] Cancer Res. 1989 Oct 1;49(19):5317-22 [2766300.001]
  • [Cites] J Biol Chem. 1991 Feb 15;266(5):3239-45 [1993697.001]
  • [Cites] J Pharmacol Exp Ther. 1991 Sep;258(3):830-6 [1653841.001]
  • [Cites] Nat Biotechnol. 2001 Mar;19(3):242-7 [11231557.001]
  • [Cites] Breast Cancer Res Treat. 2001 Jan;65(2):101-10 [11261825.001]
  • [Cites] J Biochem. 1992 Mar;111(3):396-400 [1587804.001]
  • [Cites] Adv Immunol. 1993;54:271-335 [8379464.001]
  • [Cites] EMBO J. 1994 Jan 15;13(2):286-96 [7508860.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3337-41 [7516819.001]
  • [Cites] J Biol Chem. 1994 Aug 5;269(31):20013-9 [8051085.001]
  • [Cites] J Cell Physiol. 1995 Jan;162(1):127-33 [7529235.001]
  • [Cites] Lancet. 1995 Mar 11;345(8950):615-9 [7534855.001]
  • [Cites] J Immunol. 1995 Oct 15;155(8):3938-45 [7561101.001]
  • [Cites] Am J Pathol. 1996 Jan;148(1):313-9 [8546221.001]
  • [Cites] Tumour Biol. 1996;17(4):196-219 [8685601.001]
  • [Cites] J Soc Gynecol Investig. 1996 May-Jun;3(3):99-105 [8796816.001]
  • [Cites] Am J Pathol. 1996 Nov;149(5):1519-30 [8909242.001]
  • [Cites] Biochemistry. 1998 Jan 20;37(3):844-53 [9454574.001]
  • [Cites] Mol Cell Proteomics. 2005 Feb;4(2):144-55 [15608340.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):776-83 [15810155.001]
  • [Cites] Prostate. 2006 Feb 15;66(3):283-93 [16245278.001]
  • [Cites] Proteomics. 2006 Jul;6(13):3847-61 [16767785.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1957-67 [16760258.001]
  • [Cites] Clin Chim Acta. 2006 Dec;374(1-2):25-32 [16859665.001]
  • [Cites] J Proteome Res. 2006 Nov;5(11):2909-18 [17081042.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jan 1;845(1):143-50 [16945596.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R58 [17054791.001]
  • [Cites] Proteomics. 2007 Feb;7(4):484-93 [17309111.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2993-3002 [17608509.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • [Cites] Pharmacol Ther. 2000 Mar;85(3):207-15 [10739875.001]
  • [Cites] J Oral Pathol Med. 2000 Aug;29(7):308-13 [10947246.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):946-51 [11581660.001]
  • (PMID = 18729497.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090503; United States / NCI NIH HHS / CA / R01 CA108597-05; United States / NIGMS NIH HHS / GM / R01 GM049500-12; United States / NCI NIH HHS / CA / R01 CA100104; United States / NCI NIH HHS / CA / R01CA90503; United States / NIGMS NIH HHS / GM / R01GM49500; United States / NCI NIH HHS / CA / CA090503-04; United States / NCI NIH HHS / CA / R01 CA090503-04; United States / NIGMS NIH HHS / GM / GM049500-12; United States / NIGMS NIH HHS / GM / R01 GM049500; United States / NCI NIH HHS / CA / R01CA108597; United States / NCI NIH HHS / CA / R01 CA108597; United States / NCI NIH HHS / CA / R01CA100104; United States / NCI NIH HHS / CA / R01 CA100104-05; United States / NCI NIH HHS / CA / CA100104-05; United States / NCI NIH HHS / CA / CA108597-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lectins; 0 / Membrane Glycoproteins; 0 / Peptides
  • [Other-IDs] NLM/ NIHMS81650; NLM/ PMC2630886
  •  go-up   go-down


9. Tougeron D, Tougeron-Brousseau B, Nasser Z, Benzerroug M, Lefebure B, Hamidou H, Michel P, Muraine M: Unusual iris metastasis from anal cancer: a case report. Dig Liver Dis; 2009 Jul;41(7):e1-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual iris metastasis from anal cancer: a case report.
  • We report a case of anal cancer with iris metastasis and summarize the iris metastasis literature.
  • A 69 years old woman with a history of anal cancer presented with a visual field loss.
  • Because of worse prognosis of metastatic cancer and any ocular complications, the patient was treated by radiotherapy which allowed a clinical improvement.
  • Anal carcinoma can metastasize to the iris.
  • [MeSH-major] Anus Neoplasms / pathology. Iris Neoplasms / secondary

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18294934.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


10. Satzger I, Küttler U, Völker B, Schenck F, Kapp A, Gutzmer R: Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature. Dermatology; 2010;220(1):77-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
  • Recently 12 cases of metastatic melanoma and KIT-activating mutations have been published to be successfully treated with c-KIT blockers such as imatinib, sunitinib, dasatinib or sorafenib.
  • We report here on one of our patients with KIT-activating mutation in metastatic anal mucosal melanoma, who showed a response to imatinib therapy and summarize the available literature regarding this new therapeutic option.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Melanoma / drug therapy. Piperazines / therapeutic use. Protein Kinase Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19996579.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Number-of-references] 18
  •  go-up   go-down


11. Baskın Y, Yiğitbaşı T: Clinical proteomics of breast cancer. Curr Genomics; 2010 Nov;11(7):528-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical proteomics of breast cancer.
  • Despite the lifetimes that increased in breast cancers due to the the early screening programs and new therapeutic strategies, many cases still are being lost due to the metastatic relapses.
  • For this reason, new approaches such as the proteomic techniques have currently become the prime objectives of breast cancer researches.
  • Implementation of the proteomics-based techniques is also seen as crucial if we are to develop a systems biology approach in the discovery of biomarkers of the early diagnosis, prognosis and prediction of the outcome of the breast cancer therapies.
  • In this review, we discuss the studies that have been conducted thus far, for the discovery of diagnostic, prognostic and predictive biomarkers, and evaluate the potential of the discriminating proteins identified in this research for clinical use as breast cancer biomarkers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] Anal Chem. 2000 Mar 15;72(6):1099-111 [10740846.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1037-53 [10786879.001]
  • [Cites] N Engl J Med. 2001 Feb 22;344(8):539-48 [11207349.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 1;93(15):1141-6 [11481385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Dis Markers. 2001;17(4):301-7 [11790897.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):632-5 [11830510.001]
  • [Cites] Br J Cancer. 2002 May 6;86(9):1440-3 [11986778.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] J Pathol. 2002 Oct;198(2):181-9 [12237877.001]
  • [Cites] Lab Invest. 2002 Nov;82(11):1525-33 [12429812.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):9-15 [12559171.001]
  • [Cites] Diagn Mol Pathol. 2003 Mar;12(1):27-34 [12605033.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):203-9 [14499014.001]
  • [Cites] Life Sci. 2003 Nov 7;73(25):3189-99 [14561524.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):854-62 [14566838.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):178-83 [14734467.001]
  • [Cites] Oncogene. 2004 Apr 1;23(14):2564-75 [14743203.001]
  • [Cites] J Pathol. 2004 Mar;202(3):265-73 [14991891.001]
  • [Cites] Breast Cancer Res Treat. 2004 May;85(1):13-22 [15039594.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2053-60 [15169792.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4218-26 [15205334.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6143-51 [15448001.001]
  • [Cites] Breast Cancer Res Treat. 2004 Aug;86(3):207-13 [15567937.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):791-6 [15609313.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):555-69 [15644556.001]
  • [Cites] Int J Cancer. 2005 Jul 10;115(5):783-9 [15704152.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):767-79 [15705873.001]
  • [Cites] Breast Cancer Res Treat. 2005 Mar;90(1):5-14 [15770521.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2170-8 [15781628.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):340-50 [15818618.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1197-203 [15865066.001]
  • [Cites] Proteomics. 2005 Jul;5(10):2680-8 [15892168.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] BMC Bioinformatics. 2005;6 Suppl 2:S5 [16026602.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] J Pathol. 2005 Nov;207(3):260-8 [16167361.001]
  • [Cites] Oncogene. 2006 Feb 16;25(7):981-9 [16186794.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6872-9 [16203777.001]
  • [Cites] Clin Chem. 2005 Dec;51(12):2229-35 [16223889.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):823-37 [16322324.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(1):83-90 [16322896.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11259-64 [16357129.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):261-70 [16395408.001]
  • [Cites] J Pathol. 2006 Mar;208(4):495-506 [16429394.001]
  • [Cites] Proteomics. 2006 Mar;6(6):1963-75 [16470659.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1175-83 [16489071.001]
  • [Cites] BMC Cancer. 2006;6:68 [16542425.001]
  • [Cites] Clin Chem. 2006 Jun;52(6):1045-53 [16574760.001]
  • [Cites] J Oral Pathol Med. 2006 May;35(5):292-300 [16630293.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2468-75 [16638854.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4636-44 [16651414.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1772-86 [16733261.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1727-44 [16887931.001]
  • [Cites] J Proteome Res. 2006 Nov;5(11):2947-55 [17081046.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):1-2 [17146103.001]
  • [Cites] Proteomics. 2007 Feb;7(3):474-81 [17274072.001]
  • [Cites] Anticancer Res. 2007 May-Jun;27(3A):1309-17 [17593624.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2470-6 [17594124.001]
  • [Cites] Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007 Jun;151(1):59-64 [17690741.001]
  • [Cites] J Proteome Res. 2007 Dec;6(12):4549-55 [17970587.001]
  • [Cites] BMC Cancer. 2008;8:28 [18230143.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1395-402 [18303834.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):571-9 [18385731.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1500-7 [18386930.001]
  • [Cites] Mol Cell Proteomics. 2008 Aug;7(8):1420-33 [18426791.001]
  • [Cites] Breast Cancer Res Treat. 2009 May;115(1):77-85 [18521745.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4168-74 [18593996.001]
  • [Cites] Histol Histopathol. 2009 Jan;24(1):69-76 [19012246.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Cell Biol Int Rep. 1981 Jan;5(1):93-6 [7226243.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Chirurg. 2008 Nov;79(11):1047-54 [18854964.001]
  • [Cites] Dis Markers. 2003-2004;19(4-5):229-38 [15258337.001]
  • [Cites] Ann Surg Oncol. 2004 Oct;11(10):907-14 [15383419.001]
  • [Cites] Cell Physiol Biochem. 2007;20(5):579-90 [17762184.001]
  • [Cites] Bull Acad Natl Med. 2007 Feb;191(2):361-74; discussion 374-6 [17969554.001]
  • [Cites] Am J Clin Pathol. 2008 Nov;130(5):724-30 [18854264.001]
  • (PMID = 21532837.001).
  • [ISSN] 1875-5488
  • [Journal-full-title] Current genomics
  • [ISO-abbreviation] Curr. Genomics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC3048315
  • [Keywords] NOTNLM ; Breast cancer / early diagnosis / mass spectrometry / matrix-assisted laser desorption ionisation. / micro array techniques / prognostic markers / proteomic techniques / surface enhanced laser desorption ionisation
  •  go-up   go-down


12. Karanikolas BD, Figueiredo ML, Wu L: Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res; 2009 Sep;7(9):1456-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EZH2 overexpression has been correlated with high incidence of more aggressive, metastatic prostate cancers.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Matrix Biol. 1999 Oct;18(5):455-67 [10601733.001]
  • [Cites] BJU Int. 2000 May;85(7):932-44 [10792179.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):267-85 [11159908.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):551-7 [11208850.001]
  • [Cites] Curr Opin Genet Dev. 2001 Apr;11(2):175-81 [11250141.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):950-8 [11298590.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8143-9 [11719443.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2830-5 [11880635.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Cell. 2002 Oct 18;111(2):197-208 [12408864.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):473-85 [12492490.001]
  • [Cites] Cell. 2003 Mar 7;112(5):599-606 [12628181.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1981-9 [12702592.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2728-43 [12857860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5323-35 [14532106.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):13-25 [14689577.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):481-8 [14965441.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):155-64 [15196462.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4930-7 [15077161.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):57-67 [15225548.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5759-69 [15208672.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(3):148-54 [2544306.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1721-32 [7906858.001]
  • [Cites] Nucleic Acids Res. 1995 Feb 25;23(4):628-33 [7899083.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3219-32 [9214638.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3586-95 [9584199.001]
  • [Cites] J Virol. 1998 Oct;72(10):8150-7 [9733856.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Exp Gerontol. 1999 Apr;34(2):275-87 [10363793.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1199-208 [15536069.001]
  • [Cites] DNA Cell Biol. 2005 Feb;24(2):117-25 [15699631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6942-7 [15860580.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6269-80 [16007202.001]
  • [Cites] Science. 2005 Oct 14;310(5746):306-10 [16224021.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7465-74 [16288293.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1168-74 [16489070.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):639-45 [16575874.001]
  • [Cites] Methods Enzymol. 2006;407:660-76 [16757360.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24790-802 [16766534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7 [16959882.001]
  • [Cites] J Cell Physiol. 2007 Jan;210(1):183-91 [16998811.001]
  • [Cites] Genes Dev. 2007 Jan 1;21(1):49-54 [17210787.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):347-53 [17277772.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):547-56 [17252556.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Mol Carcinog. 2008 Jun;47(6):466-77 [18058808.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] Science. 2008 Dec 12;322(5908):1695-9 [19008416.001]
  • [Cites] J Cutan Pathol. 2007 Aug;34(8):597-600 [17640228.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):419-31 [17996646.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):595-602 [17943722.001]
  • [Cites] Prostate. 2008 Feb 15;68(3):255-63 [18095286.001]
  • [Cites] Dis Markers. 2008;24(3):157-65 [18334737.001]
  • (PMID = 19723877.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092131-08; United States / NCI NIH HHS / CA / P50 CA092131; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA101904-07; United States / NCI NIH HHS / CA / R01 CA101904; United States / NCI NIH HHS / CA / CA101904-07
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; 147336-22-9 / Green Fluorescent Proteins; EC 2.1.1.- / Protein Methyltransferases; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS159142; NLM/ PMC2794652
  •  go-up   go-down


13. Methy N, Bedenne L, Bonnetain F: Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists. BMC Cancer; 2010;10:277
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials.
  • The aim of this study was to draw up an ordered list of potential surrogate endpoints for OS in digestive cancer trials, by way of a survey among clinicians and methodologists.
  • Secondary objective was to obtain their opinion on surrogacy and quality of life (QoL).
  • METHODS: In 2007 and 2008, self administered sequential questionnaires were sent to a panel of French clinicians and methodologists involved in the conduct of cancer clinical trials.
  • Then they had to suggest potential surrogate endpoints for OS in each of the following tumour sites: oesophagus, stomach, liver, pancreas, biliary tract, lymphoma, colon, rectum, and anus.
  • Half of them thought it was not relevant to study QoL as surrogate for OS.DFS, in the neoadjuvant settings or early stages, and PFS, in the non operable or metastatic settings, were ranked first, with a frequency of more than 69% in 20 out of 22 settings.
  • PFS was proposed in association with QoL in metastatic primary liver and stomach cancers (both 81%).
  • This composite endpoint was ranked second in metastatic oesophageal (69%), colorectal (56%) and anal (56%) cancers, whereas QoL alone was also suggested in most metastatic situations.Other endpoints frequently suggested were R0 resection in the neoadjuvant settings (oesophagus (69%), stomach (56%), pancreas (75%) and biliary tract (63%)) and response.
  • An unexpected endpoint was metastatic PFS in non operable oesophageal (31%) and pancreatic (44%) cancers.
  • Quality and results of surgical procedures like sphincter preservation were also cited as eligible surrogate endpoints in rectal (19%) and anal (50% in case of localized disease) cancers.
  • Except for alpha-FP kinetic in hepatocellular carcinoma (13%) and CA19-9 decline (6%) in pancreas, few endpoints based on biological or tumour markers were proposed.

  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2008 Jan;53(1):6-9 [17764823.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5218-24 [18024867.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3721-6 [18669458.001]
  • [Cites] Stat Methods Med Res. 2008 Oct;17(5):529-35 [18285442.001]
  • [Cites] Pharm Stat. 2008 Oct-Dec;7(4):263-9; discussion 270-1 [17847030.001]
  • [Cites] Int J Clin Oncol. 2009 Apr;14(2):102-11 [19390940.001]
  • [Cites] Bull Cancer. 2009 May;96(5):591-5 [19423485.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2874-80 [19414672.001]
  • [Cites] Ann Oncol. 2010 Jan;21(1):7-12 [19901012.001]
  • [Cites] Ann Oncol. 2010 Mar;21(3):518-24 [19759186.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8564-5 [16260691.001]
  • [Cites] Lancet. 2000 Jul 29;356(9227):373-8 [10972369.001]
  • [Cites] J Adv Nurs. 2000 Oct;32(4):1008-15 [11095242.001]
  • [Cites] Clin Pharmacol Ther. 2001 Mar;69(3):89-95 [11240971.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1404-11 [12663734.001]
  • [Cites] Ann Oncol. 2004 Apr;15(4):545-9 [15033657.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] J Natl Cancer Inst Monogr. 1996;(20):7-9 [8750460.001]
  • [Cites] Ann Intern Med. 1996 Oct 1;125(7):605-13 [8815760.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3662-73 [9817289.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):67-78 [15647217.001]
  • [Cites] Br J Cancer. 2005 Sep 5;93(5):504-9 [16136026.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] Stat Med. 2006 Jan 30;25(2):183-203 [16252272.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10):1344-50 [16730974.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):703-4 [16945763.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):741-6 [16945769.001]
  • [Cites] N Engl J Med. 2006 Sep 14;355(11):1114-23 [16971718.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • [Cites] J Natl Cancer Inst. 2007 Jul 4;99(13):998-1003 [17596575.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3572-5 [17704403.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4569-74 [17876008.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4562-8 [17876010.001]
  • [Cites] Oncologist. 2008;13 Suppl 2:19-21 [18434634.001]
  • (PMID = 20537166.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2904280
  •  go-up   go-down


1
Advertisement
4. Lee KC, Bradley DA, Hussain M, Meyer CR, Chenevert TL, Jacobson JA, Johnson TD, Galban CJ, Rehemtulla A, Pienta KJ, Ross BD: A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone. Neoplasia; 2007 Dec;9(12):1003-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.
  • Prostate cancer (PCa) is the most commonly diagnosed cancer in American men with a subset inevitably presenting with metastatic disease to the bone.
  • A well-recognized limitation in evaluating new treatments for metastatic PCa is the inability to use imaging to objectively assess response therapy.
  • In this study, we evaluated the feasibility of clinically translating the functional diffusion map (fDM) imaging biomarker for quantifying the spatiotemporal effects of bone tumor response in a patient treated for metastatic PCa with bone metastases.
  • Three metastatic lesions were identified for fDM analysis, all of which all demonstrated an early increase in diffusion values at 2 weeks, which increased further at 8 weeks post-treatment initiation.
  • Thus, the fDM imaging biomarker may provide a quantifiable therapeutic endpoint to assess response in patients with metastatic bone cancer.

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOSERELIN .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Nucl Med. 2007 Jun;21(4):209-15 [17581719.001]
  • [Cites] AJR Am J Roentgenol. 2007 Jun;188(6):1622-35 [17515386.001]
  • [Cites] Br J Cancer. 1978 Jul;38(1):201 [687517.001]
  • [Cites] Radiology. 1986 Nov;161(2):401-7 [3763909.001]
  • [Cites] Br J Cancer. 1996 Jan;73(1):61-4 [8554985.001]
  • [Cites] Cancer Gene Ther. 1998 Mar-Apr;5(2):101-9 [9570301.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7012-7 [9618530.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3791-9 [9731486.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):195-206 [9873906.001]
  • [Cites] Clin Nucl Med. 1999 Jan;24(1):15-20 [9890487.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1457-66 [9815831.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7852-9 [15585617.001]
  • [Cites] MAGMA. 2004 Dec;17(3-6):249-59 [15580371.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):831-7 [15720810.001]
  • [Cites] Semin Nucl Med. 2005 Apr;35(2):135-42 [15765376.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9 [15805192.001]
  • [Cites] Neoplasia. 2005 May;7(5):475-85 [15967100.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5223-32 [16033840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64 [16267128.001]
  • [Cites] Gene Ther. 2006 Jan;13(2):127-37 [16163381.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3461-7 [10550143.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1754-9 [10677530.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1005-10 [10871748.001]
  • [Cites] Neoplasia. 1999 Jun;1(2):113-7 [10933044.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36 [11121466.001]
  • [Cites] Semin Nucl Med. 2001 Jul;31(3):206-11 [11430527.001]
  • [Cites] Neoplasia. 2002 May-Jun;4(3):255-62 [11988845.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):581-7 [12813138.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):336-43 [12926229.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2942-53 [15254062.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):275-82 [15468951.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] Mol Ther. 2004 Nov;10(5):916-28 [15509509.001]
  • [Cites] Br J Cancer. 1977 Mar;35(3):292-8 [856236.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4687-92 [16651420.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):259-67 [16756718.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3984-90 [16921051.001]
  • [Cites] Eur Radiol. 2006 Dec;16(12):2637-43 [16909220.001]
  • [Cites] NMR Biomed. 2006 Dec;19(8):1035-42 [16894643.001]
  • [Cites] Pediatr Radiol. 2006 Dec;36(12):1306-11 [17031633.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):443-50 [17255264.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1488-92 [17332293.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1839-46 [17363540.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3524-8 [17440058.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2351-61 [17786228.001]
  • (PMID = 18084607.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32CA009357; United States / NCI NIH HHS / CA / P01 CA087634; United States / NCI NIH HHS / CA / P01CA87634; United States / NCI NIH HHS / CA / P50CA93990; United States / NCI NIH HHS / CA / P50CA69568; United States / NCI NIH HHS / CA / P01CA093900; United States / NCI NIH HHS / CA / T32 CA009357; United States / NCI NIH HHS / CA / P01 CA085878; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / P01CA85878; United States / NCI NIH HHS / CA / P50 CA093990; United States / NCI NIH HHS / CA / P01 CA093900
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 0F65R8P09N / Goserelin; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC2134897
  • [Keywords] NOTNLM ; Metastatic prostate cancer / androgen deprivation therapy / diffusion MRI / functional diffusion map / imaging biomarker
  •  go-up   go-down


15. Saba NF, Wang X, Müller S, Tighiouart M, Cho K, Nie S, Chen Z, Shin DM: Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug. Head Neck; 2009 Apr;31(4):475-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug.
  • We investigated expression levels of folate receptor in squamous cell carcinoma of the head and neck (SCCHN) to evaluate folate receptor as a target for nanotherapy.
  • Folate receptor expression in primary tumors of the metastatic group strongly correlated with the corresponding lymph node metastases (p = .0002).
  • Folate receptor expression was inversely correlated with disease-free survival in nonmetastatic (p = .0048), metastatic (p = .0127), and lymph node metastases (p <.001) groups, and with overall survival in the lymph node metastases group (p <.0001).

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):498-505 [18342661.001]
  • [Cites] Bioconjug Chem. 2002 Nov-Dec;13(6):1200-10 [12440854.001]
  • [Cites] Bioconjug Chem. 2002 Nov-Dec;13(6):1328-35 [12440870.001]
  • [Cites] Int J Pharm. 2003 Jan 30;251(1-2):85-97 [12527178.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1055-8 [15094205.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5572-6 [2062838.001]
  • [Cites] Biochem J. 1993 May 1;291 ( Pt 3):855-60 [8387781.001]
  • [Cites] J Cell Sci. 1993 Sep;106 ( Pt 1):423-30 [8270640.001]
  • [Cites] J Biol Chem. 1994 Feb 4;269(5):3198-204 [8106354.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):463-7 [8123474.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3905-11 [8033114.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] Int J Cancer. 1997 Dec 10;73(6):859-64 [9399666.001]
  • [Cites] Anal Biochem. 2005 Mar 15;338(2):284-93 [15745749.001]
  • [Cites] Curr Drug Deliv. 2005 Jul;2(3):243-52 [16305426.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):243-50 [16453285.001]
  • [Cites] Bioorg Med Chem. 2002 Jul;10(7):2397-414 [11983537.001]
  • (PMID = 19072997.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA119338-04; United States / NCI NIH HHS / CA / P50 CA128613; United States / NCI NIH HHS / CA / U54 CA119338; United States / NCI NIH HHS / CA / U54 CA119338-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface; 935E97BOY8 / Folic Acid; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS78522; NLM/ PMC2658731
  •  go-up   go-down


16. Cai W, Ebrahimnejad A, Chen K, Cao Q, Li ZB, Tice DA, Chen X: Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging; 2007 Dec;34(12):2024-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: EphA2 receptor tyrosine kinase is significantly overexpressed in a wide variety of cancer types.
  • High EphA2 expression has been correlated with increased metastatic potential and poor patient survival.
  • Although many recent reports have focused on blocking the EphA2 signaling pathway in cancer, the in vivo imaging of EphA2 has not yet been investigated.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 1995 Dec;36(12 ):2363-71 [8523133.001]
  • [Cites] Cell. 1998 May 29;93(5):741-53 [9630219.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Feb;13(1):75-85 [11750881.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2840-7 [12019162.001]
  • [Cites] Curr Cancer Drug Targets. 2005 May;5(3):149-57 [15892616.001]
  • [Cites] Curr Pharm Des. 2004;10(27):3431-42 [15544526.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1115-23 [16133391.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9673-81 [17018625.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6910-8 [16061675.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:18S-27S [15653648.001]
  • [Cites] Neoplasia. 2006 Jan;8(1):18-30 [16533422.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7011-26 [12370823.001]
  • [Cites] J Nucl Med. 2006 Jul;47(7):1172-80 [16818952.001]
  • [Cites] Exp Eye Res. 2006 Apr;82(4):664-73 [16359662.001]
  • [Cites] Nucl Med Biol. 2006 Oct;33(7):883-9 [17045168.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):304-10 [17268029.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8476-80 [14679012.001]
  • [Cites] Prostate. 1999 Dec 1;41(4):275-80 [10544301.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):850-8 [17262214.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2301-6 [11280802.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):910-9 [14871820.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70 [17077358.001]
  • [Cites] Exp Cell Res. 2000 Nov 1;260(2):365-73 [11035932.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):46974-9 [12351647.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5145-50 [15297418.001]
  • [Cites] Oncogene. 2000 Dec 7;19(52):6043-52 [11146556.001]
  • [Cites] Neuron. 1996 Jul;17(1):9-19 [8755474.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7050-8 [16849550.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):773-6 [12557049.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2624-33 [17121909.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):613-8 [12576426.001]
  • [Cites] Nucl Med Biol. 2003 May;30(4):417-27 [12767399.001]
  • [Cites] Oncol Rep. 2004 Mar;11(3):605-11 [14767510.001]
  • [Cites] J Nucl Med. 2006 Dec;47(12 ):2048-56 [17138749.001]
  • [Cites] Cancer Sci. 2004 Feb;95(2):136-41 [14965363.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1250-5 [16258537.001]
  • [Cites] Nat Nanotechnol. 2007 Jan;2(1):47-52 [18654207.001]
  • [Cites] J Nucl Med. 1992 Sep;33(9):1685-91 [1517844.001]
  • [Cites] Anal Biochem. 1984 Oct;142(1):68-78 [6440451.001]
  • [Cites] Cancer Gene Ther. 2004 Nov;11(11):757-66 [15359289.001]
  • [Cites] Cancer. 2006 Nov 15;107(10):2425-35 [17041885.001]
  • (PMID = 17673999.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 114747; United States / NCI NIH HHS / CA / R21 CA 102123; United States / NIBIB NIH HHS / EB / R21 EB 001785; United States / NCI NIH HHS / CA / R24 CA 93862; United States / NCI NIH HHS / CA / U54 CA 119367
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 64Cu-DOTA-1C1; 0 / Antibodies, Monoclonal; 0 / Organometallic Compounds; 0 / Radiopharmaceuticals; EC 2.7.10.1 / Receptor, EphA2
  •  go-up   go-down


17. Misra UK, Deedwania R, Pizzo SV: Binding of activated alpha2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK. J Biol Chem; 2005 Jul 15;280(28):26278-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Binding of activated alpha2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK.
  • Recently, we reported that binding of receptor-recognized forms of the proteinase inhibitor alpha2-macroglobulin (alpha2M*) to GRP78 on the cell surface of 1-LN human prostate cancer cells induces mitogenic signaling and cellular proliferation.
  • Exposure of 1-LN cells to alpha2M* caused a 2- to 3-fold increase in phosphorylated PAK-2 and a similar increase in its kinase activity toward myelin basic protein.
  • Treatment of 1-LN cells with alpha2M* caused translocation of PAK-2 in association with NCK to the cell surface as evidenced by the co-immunoprecipitation of PAK-2 and NCK in the GRP78 immunoprecipitate from plasma membranes. alpha2M*-induced activation of PAK-2 was inhibited by prior incubation of the cells with specific inhibitors of tyrosine kinases and phosphatidylinositol 3-kinase.
  • In conclusion, we show for the first time the activation of PAK-2 in 1-LN prostate cancer cells by a proteinase inhibitor, alpha2-macroglobulin.
  • These studies suggest a mechanism by which alpha2M* enhances the metastatic potential of these cells.

  • Genetic Alliance. consumer health - Prostate cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Biochem. 2000;69:217-45 [10966458.001]
  • [Cites] Cell. 2000 Oct 13;103(2):193-200 [11057893.001]
  • [Cites] Arch Biochem Biophys. 2000 Nov 1;383(1):135-41 [11097186.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14346-51 [11121037.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):547-57 [10880354.001]
  • [Cites] Methods Enzymol. 2001;333:343-8 [11400350.001]
  • [Cites] Trends Biochem Sci. 2001 Aug;26(8):504-10 [11504627.001]
  • [Cites] J Cell Biochem. 2001;82(2):260-70 [11527151.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):4069-78 [11733496.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):148-54 [11857399.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Annu Rev Cell Dev Biol. 2002;18:575-99 [12142265.001]
  • [Cites] J Biol Chem. 2002 Nov 1;277(44):42082-7 [12194978.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):57-63 [12496764.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7247-52 [12777619.001]
  • [Cites] Cancer Metastasis Rev. 2003 Dec;22(4):385-93 [12884913.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36868-75 [12821664.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38675-85 [12853446.001]
  • [Cites] Annu Rev Biochem. 2003;72:743-81 [12676796.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):70-8 [14688311.001]
  • [Cites] Cell Signal. 2004 Apr;16(4):487-96 [14709337.001]
  • [Cites] Trends Cell Biol. 2004 Jan;14(1):20-8 [14729177.001]
  • [Cites] Endocr Rev. 2004 Apr;25(2):276-308 [15082523.001]
  • [Cites] Cell Signal. 2004 Aug;16(8):929-38 [15157672.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):25935-8 [15070890.001]
  • [Cites] FEBS Lett. 2004 Jul 30;571(1-3):1-8 [15280008.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):275-84 [15380518.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Biochem J. 1993 Mar 15;290 ( Pt 3):885-91 [7681282.001]
  • [Cites] J Biol Chem. 1994 Jul 15;269(28):18303-6 [7518427.001]
  • [Cites] Annu Rev Biochem. 1994;63:601-37 [7979249.001]
  • [Cites] Cell. 1995 Apr 7;81(1):53-62 [7536630.001]
  • [Cites] Science. 1995 Jul 14;269(5221):221-3 [7618083.001]
  • [Cites] J Biol Chem. 1995 Dec 29;270(52):31321-30 [8537403.001]
  • [Cites] J Biol Chem. 1997 Jan 3;272(1):497-502 [8995289.001]
  • [Cites] J Urol. 1998 Jan;159(1):297-303 [9400498.001]
  • [Cites] J Biol Chem. 1998 Apr 3;273(14):8137-44 [9525917.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):28238-46 [9774445.001]
  • [Cites] J Biol Chem. 1998 Oct 30;273(44):28733-9 [9786869.001]
  • [Cites] Clin Chem. 1998 Dec;44(12):2471-9 [9836714.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):797-806 [9989831.001]
  • [Cites] Curr Opin Cell Biol. 1999 Feb;11(1):54-60 [10047522.001]
  • [Cites] Genes Dev. 1999 May 15;13(10):1211-33 [10346810.001]
  • [Cites] Trends Biochem Sci. 1999 Sep;24(9):350-5 [10470034.001]
  • [Cites] Mt Sinai J Med. 2004 Oct;71(5):289-97 [15543429.001]
  • [Cites] Nat Cell Biol. 1999 Sep;1(5):253-9 [10559936.001]
  • [Cites] Genes Dev. 1999 Nov 15;13(22):2905-27 [10579998.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(2):453-61 [10611223.001]
  • (PMID = 15908432.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL024066; United States / NHLBI NIH HHS / HL / R37 HL024066; United States / NHLBI NIH HHS / HL / HL-24066
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actin Depolymerizing Factors; 0 / Actins; 0 / BAD protein, human; 0 / Carrier Proteins; 0 / Enzyme Inhibitors; 0 / Heat-Shock Proteins; 0 / Microfilament Proteins; 0 / Molecular Chaperones; 0 / Myelin Basic Protein; 0 / Protein Isoforms; 0 / RNA, Double-Stranded; 0 / RNA, Messenger; 0 / alpha-Macroglobulins; 0 / bcl-Associated Death Protein; 0 / molecular chaperone GRP78; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / LIMK1 protein, human; EC 2.7.11.1 / Lim Kinases; EC 2.7.11.1 / PAK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / p21-Activated Kinases; EC 3.6.5.2 / rac GTP-Binding Proteins
  • [Other-IDs] NLM/ NIHMS4211; NLM/ PMC1201553
  •  go-up   go-down


18. Lauer-Fields JL, Whitehead JK, Li S, Hammer RP, Brew K, Fields GB: Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem; 2008 Jul 18;283(29):20087-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unregulated activities of the matrix metalloproteinase (MMP) family have been implicated in primary and metastatic tumor growth, angiogenesis, and pathological degradation of extracellular matrix components, such as collagen and laminin.
  • Enhanced selectivity could be achieved by taking advantage of differences in substrate secondary binding sites (exosites) within the MMP family.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1996 Jun;10(8):927-30 [8666171.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2446-51 [8999957.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7608-16 [9065415.001]
  • [Cites] Biol Chem. 1998 Feb;379(2):185-91 [9524070.001]
  • [Cites] Nature. 1998 Apr 16;392(6677):666-7 [9565027.001]
  • [Cites] Arch Biochem Biophys. 1998 Jun 1;354(1):24-30 [9633594.001]
  • [Cites] Chem Biol. 1999 Feb;6(2):63-70 [10021421.001]
  • [Cites] Science. 1999 Jun 4;284(5420):1667-70 [10356396.001]
  • [Cites] J Biomol Tech. 2004 Dec;15(4):305-16 [15585827.001]
  • [Cites] Biochem J. 2005 Nov 15;392(Pt 1):127-34 [16008524.001]
  • [Cites] Chem Biol Drug Des. 2006 Jan;67(1):2-4 [16492143.001]
  • [Cites] Chem Biol. 2000 Feb;7(2):119-32 [10662694.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4273-8 [10725403.001]
  • [Cites] J Biol Chem. 2000 May 5;275(18):13282-90 [10788434.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27964-72 [10823838.001]
  • [Cites] J Biol Chem. 2000 Sep 22;275(38):29610-7 [10871619.001]
  • [Cites] Proteins. 2000;Suppl 4:63-71 [11013401.001]
  • [Cites] Biochemistry. 2000 Dec 5;39(48):14960-7 [11101312.001]
  • [Cites] Front Biosci. 2006;11:3100-20 [16720379.001]
  • [Cites] J Mol Biol. 2006 Sep 8;362(1):78-88 [16890240.001]
  • [Cites] J Biol Chem. 2006 Sep 8;281(36):26528-39 [16825197.001]
  • [Cites] J Biol Chem. 2006 Dec 15;281(50):38302-13 [17065155.001]
  • [Cites] FEBS J. 2007 Mar;274(5):1246-55 [17298441.001]
  • [Cites] Curr Pharm Des. 2007;13(3):333-46 [17313364.001]
  • [Cites] Biochemistry. 2007 Mar 27;46(12):3724-33 [17338550.001]
  • [Cites] J Mol Biol. 2007 May 11;368(4):1101-13 [17379243.001]
  • [Cites] Biochem J. 2007 Aug 15;406(1):147-55 [17516913.001]
  • [Cites] J Am Chem Soc. 2007 Aug 29;129(34):10408-17 [17672455.001]
  • [Cites] Protein Sci. 2007 Sep;16(9):1905-13 [17660250.001]
  • [Cites] Structure. 2007 Oct;15(10):1159-61 [17937904.001]
  • [Cites] Structure. 2007 Oct;15(10):1227-36 [17937912.001]
  • [Cites] Biopolymers. 2000;55(6):436-50 [11304671.001]
  • [Cites] Biochemistry. 2001 May 15;40(19):5795-803 [11341845.001]
  • [Cites] FEBS Lett. 2001 Aug 17;503(2-3):158-62 [11513874.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):534-40 [11544020.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):4485-91 [11694539.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Biochemistry. 2002 May 14;41(19):6054-64 [11994000.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2002 Jul;58(Pt 7):1182-92 [12077439.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):657-72 [12209155.001]
  • [Cites] Mol Biotechnol. 2002 Sep;22(1):51-86 [12353914.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1095-105 [12437092.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):18140-5 [12642591.001]
  • [Cites] Biomacromolecules. 2003 May-Jun;4(3):518-28 [12741765.001]
  • [Cites] Biochem J. 2004 Feb 1;377(Pt 3):775-9 [14533979.001]
  • [Cites] Protein Sci. 2004 Apr;13(4):893-902 [15010541.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):166-73 [15113693.001]
  • [Cites] J Comput Aided Mol Des. 2003 Dec;17(12):837-48 [15124932.001]
  • [Cites] EMBO J. 2004 Aug 4;23(15):3020-30 [15257288.001]
  • [Cites] Biochemistry. 2004 Sep 14;43(36):11474-81 [15350133.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):43336-44 [15292230.001]
  • [Cites] Biochem J. 1989 Oct 1;263(1):201-6 [2557822.001]
  • [Cites] J Biol Chem. 1992 Apr 5;267(10):6776-81 [1313021.001]
  • [Cites] J Theor Biol. 1991 Dec 21;153(4):585-602 [1666905.001]
  • [Cites] J Biol Chem. 1992 May 15;267(14):9612-8 [1315762.001]
  • [Cites] Biochem J. 1993 May 1;291 ( Pt 3):847-54 [8489511.001]
  • [Cites] J Biol Chem. 1994 Aug 19;269(33):20952-7 [8063713.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):5872-6 [7890717.001]
  • [Cites] J Biol Chem. 1995 May 12;270(19):11555-66 [7744795.001]
  • [Cites] Biochem J. 1995 Jun 1;308 ( Pt 2):645-51 [7772054.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Nov 2;216(1):329-37 [7488108.001]
  • (PMID = 18499673.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 98799; United States / NIAMS NIH HHS / AR / AR040994-15A1; United States / NIAMS NIH HHS / AR / R01 AR040994; United States / NIAMS NIH HHS / AR / R01 AR040994-15A1; United States / NCI NIH HHS / CA / R01 CA098799
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2459303
  •  go-up   go-down


19. Harikumar KB, Sung B, Pandey MK, Guha S, Krishnan S, Aggarwal BB: Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway. Mol Pharmacol; 2010 May;77(5):818-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Agents that can enhance tumor cell apoptosis and inhibit invasion have potential for the treatment of cancer.
  • Overall, our results demonstrate that escin inhibits activation of NF-kappaB through inhibition of IKK, leading to down-regulation of NF-kappaB-regulated cell survival and metastatic gene products and thus resulting in sensitization of cells to cytokines and chemotherapeutic agents.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nat Prod. 1999 Nov;62(11):1510-3 [10579862.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2008 Jan;56(1):12-6 [18175967.001]
  • [Cites] Acta Pol Pharm. 2000 Jan-Feb;57(1):73-8 [10846802.001]
  • [Cites] Methods Enzymol. 2000;319:585-602 [10907546.001]
  • [Cites] Pharmacol Res. 2001 Sep;44(3):183-93 [11529685.001]
  • [Cites] Br J Sports Med. 2002 Jun;36(3):183-8 [12055112.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):203-8 [15380510.001]
  • [Cites] Acta Pharmacol Sin. 2004 Oct;25(10):1267-75 [15456527.001]
  • [Cites] Arzneimittelforschung. 1976 Feb;26(2):225-35 [947203.001]
  • [Cites] Gen Pharmacol. 1994 Oct;25(6):1213-9 [7875547.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1996 Aug;44(8):1454-64 [8795266.001]
  • [Cites] Eur J Pharmacol. 1996 Nov 14;315(2):227-33 [8960888.001]
  • [Cites] Biol Pharm Bull. 1997 Oct;20(10):1092-5 [9353571.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):20551-5 [9685412.001]
  • [Cites] Bioorg Med Chem. 1998 Jul;6(7):1019-23 [9730238.001]
  • [Cites] Eur J Pharmacol. 1999 May 28;373(1):63-70 [10408252.001]
  • [Cites] Zhong Xi Yi Jie He Xue Bao. 2004 Nov;2(6):426-8 [15539019.001]
  • [Cites] J Zhejiang Univ Sci B. 2005 Jan;6(1):28-32 [15593388.001]
  • [Cites] Clin Ther. 2004 Dec;26(12):2045-55 [15823768.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1614-20; discussion 1621-2 [16311848.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1459-66 [16818504.001]
  • [Cites] J Pharm Biomed Anal. 2006 Aug 28;41(5):1657-65 [16621416.001]
  • [Cites] Sci STKE. 2006 Oct 17;2006(357):re13 [17047224.001]
  • [Cites] Oncogene. 2006 Oct 30;25(51):6685-705 [17072322.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1385-97 [16953224.001]
  • [Cites] Planta Med. 2007 Mar;73(3):285-8 [17310430.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2727-35 [17110449.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2286-95 [17609425.001]
  • [Cites] Pol J Pharmacol. 1999 Nov-Dec;51(6):511-5 [10817529.001]
  • (PMID = 20103608.001).
  • [ISSN] 1521-0111
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA124787; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA124787-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / DNA Primers; 0 / NF-kappa B; 6805-41-0 / Escin
  • [Other-IDs] NLM/ PMC2872971
  •  go-up   go-down


20. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR: Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res; 2010 Dec 1;16(23):5664-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
  • PURPOSE: Brain metastases of breast cancer appear to be increasing in incidence, confer significant morbidity, and threaten to compromise gains made in systemic chemotherapy.
  • Herein, we answer this question by measuring BTB passive integrity, chemotherapeutic drug uptake, and anticancer efficacy in vivo in two breast cancer models that metastasize preferentially to brain.
  • Neither drug significantly decreased the experimental brain metastatic ability of 231-BR-Her2 tumor cells.
  • CONCLUSIONS: This work shows that the BTB remains a significant impediment to standard chemotherapeutic delivery and efficacy in experimental brain metastases of breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Pharm Res. 2009 Nov;26(11):2486-94 [19774344.001]
  • [Cites] J Nucl Med. 2010 May;51(5):775-81 [20395330.001]
  • [Cites] J Appl Physiol (1985). 2010 Apr;108(4):962-7 [20110542.001]
  • [Cites] Brain Res Rev. 2010 Sep 24;64(2):328-63 [20685221.001]
  • [Cites] Neuro Oncol. 2010 Oct;12(10):1043-9 [20501632.001]
  • [Cites] J Neurooncol. 1994;20(2):121-39 [7807190.001]
  • [Cites] Ann Oncol. 1994 Dec;5(10):951-3 [7696168.001]
  • [Cites] Cancer. 1995 Jul 15;76(2):232-6 [8625097.001]
  • [Cites] Anticancer Drugs. 1996 Jan;7(1):78-86 [8742102.001]
  • [Cites] J Pharm Sci. 1997 Aug;86(8):881-4 [9269863.001]
  • [Cites] Drug Metab Dispos. 2007 Apr;35(4):660-6 [17237155.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4190-8 [17483330.001]
  • [Cites] J Cereb Blood Flow Metab. 1997 Nov;17(11):1239-53 [9390656.001]
  • [Cites] Ann Biomed Eng. 1998 Sep-Oct;26(5):764-74 [9779948.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):824-34 [15897247.001]
  • [Cites] Brain Res. 2005 Jul 5;1049(1):8-14 [15935996.001]
  • [Cites] Am J Pathol. 2005 Oct;167(4):913-20 [16192626.001]
  • [Cites] Neurosurgery. 2005 Nov;57(5 Suppl):S54-65; discusssion S1-4 [16237290.001]
  • [Cites] Nucl Med Biol. 2005 Oct;32(7):719-25 [16243647.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):935-44 [16603601.001]
  • [Cites] Expert Rev Neurother. 2006 Aug;6(8):1199-209 [16893347.001]
  • [Cites] Clin Pharmacokinet. 2006;45(9):871-903 [16928151.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5770-6 [17020983.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1023-6 [17187362.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1623-4 [17363511.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1648-55 [17363517.001]
  • [Cites] Clin Cancer Res. 2007 Mar 15;13(6):1663-74 [17363519.001]
  • [Cites] J Bone Miner Res. 2001 Aug;16(8):1486-95 [11499871.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):341-5 [11809675.001]
  • [Cites] J Pharm Biomed Anal. 2002 Nov 7;30(4):1063-74 [12408897.001]
  • [Cites] J Clin Invest. 2002 Nov;110(9):1309-18 [12417570.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2972-7 [12784331.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2849-55 [12855665.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):5114-7 [12941842.001]
  • [Cites] Methods Mol Med. 2003;89:177-90 [12958420.001]
  • [Cites] Methods Mol Med. 2003;89:193-208 [12958421.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2114-20 [14522368.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1845-54 [14602869.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):379-82 [14746856.001]
  • [Cites] Clin Exp Metastasis. 2004;21(2):107-18 [15168728.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3608-17 [15337811.001]
  • [Cites] Cancer Treat Rep. 1977 Jul;61(4):527-31 [884690.001]
  • [Cites] Arch Neurol. 1977 Sep;34(9):523-6 [889492.001]
  • [Cites] Stroke. 1979 Jan-Feb;10(1):62-7 [432901.001]
  • [Cites] J Cereb Blood Flow Metab. 1983 Mar;3(1):8-32 [6822623.001]
  • [Cites] J Neurosurg. 1983 Aug;59(2):304-10 [6864299.001]
  • [Cites] J Neurooncol. 1984;2(3):205-18 [6502195.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):832-9 [3755076.001]
  • [Cites] Ann N Y Acad Sci. 1988;529:21-30 [3395069.001]
  • [Cites] Acta Neurochir (Wien). 1990;104(1-2):13-6 [2386084.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):641-5 [2021551.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):972-80 [1735089.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(4):251-60 [1643692.001]
  • [Cites] Am J Pathol. 1992 Nov;141(5):1115-24 [1443046.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Apr;269(1):22-7 [8169829.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(6):465-71 [7923556.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2295-305 [17538176.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2306-12 [17538177.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] Pharm Res. 2007 Sep;24(9):1745-58 [17619998.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Feb;61(2):223-9 [17443325.001]
  • [Cites] Brain Res. 2008 Jan 16;1189:1-11 [18061148.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4658-66 [18628481.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 6;100(15):1092-103 [18664652.001]
  • [Cites] BMC Cancer. 2008;8:228 [18691423.001]
  • [Cites] Clin Exp Metastasis. 2008;25(7):799-810 [18649117.001]
  • [Cites] J Cell Physiol. 2009 Mar;218(3):612-22 [19016245.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):182-7 [18701427.001]
  • [Cites] Cell Mol Neurobiol. 2009 May;29(3):309-16 [18987969.001]
  • [Cites] PLoS One. 2009;4(6):e5857 [19516901.001]
  • [Cites] Nature. 2009 Jun 18;459(7249):1005-9 [19421193.001]
  • [Cites] Br J Cancer. 2009 Jul 7;101(1):38-47 [19513066.001]
  • [Cites] CNS Neurol Disord Drug Targets. 2009 Jun;8(3):195-204 [19601817.001]
  • [Cites] Int J Clin Oncol. 2009 Aug;14(4):299-306 [19705239.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6148-57 [19789319.001]
  • [Cites] J Transl Med. 2009;7:88 [19840404.001]
  • [Cites] Nat Med. 2010 Jan;16(1):116-22 [20023634.001]
  • [CommentIn] Clin Cancer Res. 2010 Dec 1;16(23):5605-7 [21045085.001]
  • (PMID = 20829328.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS052484; United States / NINDS NIH HHS / NS / R01 NS052484-04; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ NIHMS234693; NLM/ PMC2999649
  •  go-up   go-down


21. Porter CJ, Matthews JM, Mackay JP, Pursglove SE, Schmidberger JW, Leedman PJ, Pero SC, Krag DN, Wilce MC, Wilce JA: Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation. BMC Struct Biol; 2007 Sep 25;7:58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation.
  • Grb7 is frequently overexpressed in invasive and metastatic human cancers and is implicated in cancer progression via its interaction with the ErbB2 receptor and focal adhesion kinase (FAK) that play critical roles in cell proliferation and migration.
  • It is thus a prime target for the development of novel anti-cancer therapies.
  • Recently, an inhibitory peptide (G7-18NATE) has been developed which binds specifically to the Grb7 SH2 domain and is able to attenuate cancer cell proliferation and migration in various cancer cell lines.
  • We propose that the current study will assist with the development of second generation Grb7 SH2 domain inhibitors, potentially leading to novel inhibitors of cancer cell migration and invasion.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Ther Targets. 2003 Apr;7(2):215-34 [12667099.001]
  • [Cites] Br J Cancer. 2007 May 21;96(10):1520-5 [17426702.001]
  • [Cites] J Biomol NMR. 2003 Nov;27(3):205-19 [12975581.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):206-15 [15661544.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12502-10 [8647858.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1997 Jul 1;53(Pt 4):448-55 [15299911.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):491-8 [16595785.001]
  • [Cites] J Mol Biol. 2002 Feb 1;315(5):1167-77 [11827484.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30896-905 [10521483.001]
  • [Cites] Cell. 1993 Mar 12;72(5):779-90 [7680960.001]
  • [Cites] Nature. 1993 Mar 4;362(6415):87-91 [7680435.001]
  • [Cites] Adv Protein Chem. 2002;61:161-210 [12461824.001]
  • [Cites] Biochemistry. 2000 Dec 26;39(51):15860-9 [11123912.001]
  • [Cites] Exp Cell Res. 2002 Jan 15;272(2):93-108 [11777334.001]
  • [Cites] J Med Chem. 1999 Mar 25;42(6):971-80 [10090780.001]
  • [Cites] Dev Biol. 1997 Apr 1;184(1):150-64 [9142991.001]
  • [Cites] Protein Sci. 2005 Jun;14(6):1556-69 [15930003.001]
  • [Cites] Front Biosci. 2004 Jan 1;9:192-200 [14766359.001]
  • [Cites] Biochemistry. 1997 Aug 19;36(33):10006-14 [9254595.001]
  • [Cites] Mol Cell. 2005 Oct 28;20(2):325-33 [16246733.001]
  • [Cites] EMBO J. 1994 Mar 15;13(6):1331-40 [7907978.001]
  • [Cites] Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S183-7 [16113095.001]
  • [Cites] Biochemistry. 1996 Aug 27;35(34):11062-9 [8780508.001]
  • [Cites] Eur Biophys J. 2005 Jul;34(5):454-60 [15841400.001]
  • [Cites] Biopolymers. 2007;88(2):174-81 [17206629.001]
  • [Cites] J Biomol NMR. 1992 Nov;2(6):661-5 [1490109.001]
  • [Cites] Acta Crystallogr A. 1991 Mar 1;47 ( Pt 2):110-9 [2025413.001]
  • [Cites] EMBO J. 2004 Apr 7;23(7):1441-51 [15029250.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):505-15 [16069815.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):24425-30 [10446223.001]
  • [Cites] J Biol Chem. 1996 Sep 20;271(38):23588-93 [8798570.001]
  • [Cites] Growth Factors. 2005 Sep;23(3):193-201 [16243711.001]
  • [Cites] Nat Struct Biol. 1996 Jul;3(7):586-9 [8673601.001]
  • [Cites] J Biol Chem. 1997 Mar 28;272(13):8490-7 [9079677.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4845-52 [11726652.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):11918-26 [11809769.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55 [15299926.001]
  • [Cites] J Biol Chem. 1996 Apr 12;271(15):8882-6 [8621530.001]
  • [Cites] Biochemistry. 1964 Mar;3:297-317 [14155091.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2003 Jul;59(Pt 7):1131-7 [12832755.001]
  • [Cites] Biochem J. 2005 Jun 1;388(Pt 2):393-406 [15901248.001]
  • [Cites] Anal Biochem. 1989 Nov 1;182(2):319-26 [2610349.001]
  • [Cites] Cell. 1993 Mar 12;72(5):767-78 [7680959.001]
  • [Cites] Expert Rev Mol Med. 2003 May;5(14):1-11 [14585167.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7771-8 [10713090.001]
  • [Cites] Cell. 2004 Jan 23;116(2):191-203 [14744431.001]
  • [Cites] FEBS Lett. 2001 Mar 30;493(2-3):106-11 [11287005.001]
  • [Cites] Semin Oncol. 2006 Aug;33(4):407-20 [16890796.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2288-94 [15572783.001]
  • [Cites] Oncogene. 2001 Oct 1;20(44):6315-21 [11607834.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7784-8 [7544002.001]
  • [Cites] Mol Cell Biol. 1999 Sep;19(9):6217-28 [10454568.001]
  • [Cites] J Biomol NMR. 1998 Jan;11(1):97-102 [9566315.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3 [15299374.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2659-67 [9006901.001]
  • [Cites] Biophys J. 1981 Dec;36(3):575-88 [7326325.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7717-24 [9516479.001]
  • [Cites] Nature. 1992 Aug 20;358(6388):646-53 [1379696.001]
  • [Cites] J Mol Biol. 1971 Feb 14;55(3):379-400 [5551392.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28911-7 [10893408.001]
  • [Cites] J Biol Chem. 2003 Apr 11;278(15):13257-64 [12551896.001]
  • [Cites] J Biol Chem. 1996 Nov 29;271(48):30942-9 [8940081.001]
  • [Cites] Cancer Res. 1997 Jan 1;57(1):28-31 [8988034.001]
  • [Cites] J Biomol NMR. 2002 May;23(1):77-8 [12061724.001]
  • [Cites] Nature. 1996 May 23;381(6580):272 [8692262.001]
  • [Cites] J Mol Biol. 1995 Nov 17;254(1):86-95 [7473762.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45655-61 [12223469.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):5-9 [9125150.001]
  • (PMID = 17894853.001).
  • [ISSN] 1472-6807
  • [Journal-full-title] BMC structural biology
  • [ISO-abbreviation] BMC Struct. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U54 CA132383; United States / NCI NIH HHS / CA / U56 CA096286
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GRB7 protein, human; 0 / Ligands; 0 / Peptides, Cyclic; 149058-53-7 / GRB7 Adaptor Protein
  • [Other-IDs] NLM/ PMC2131756
  •  go-up   go-down


22. Cao Y, Liao C, Tan A, Liu L, Mo Z, Gao F: Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials. Colorectal Dis; 2010 Jan;12(1):16-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.
  • OBJECTIVE: This meta-analysis was performed to evaluate the efficacy and safety of capecitabine plus oxaliplatin vs fluorouracil (FU) plus oxaliplatin as first line treatment for metastatic or advanced colorectal cancer.
  • CONCLUSION: The effect of capecitabine plus oxaliplatin regimen is similar to FU plus oxaliplatin regimen as first line treatment for metastatic colorectal cancer, but it offers advantages of simplicity and convenience to administer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19220378.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K, Narimatsu H: Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci U S A; 2005 Mar 22;102(12):4572-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells.
  • These findings indicated that the core structures of O-glycans are profoundly involved in the metastatic capacity of cancer cells.
  • [MeSH-minor] Animals. Caco-2 Cells. Cell Line, Tumor. Cell Movement / physiology. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Down-Regulation. Humans. Immunohistochemistry. In Vitro Techniques. Lung Neoplasms / enzymology. Lung Neoplasms / genetics. Lung Neoplasms / secondary. Mice. Mice, Inbred BALB C. Stomach Neoplasms / enzymology. Stomach Neoplasms / genetics. Transfection

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Biol Chem. 2002 Jun 21;277(25):22623-38 [11925450.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):573-84 [12407114.001]
  • [Cites] Anal Biochem. 1976 Aug;74(2):466-76 [962103.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2051-5 [6952252.001]
  • [Cites] J Natl Cancer Inst. 1983 Aug;71(2):231-51 [6576183.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2405-14 [3886132.001]
  • [Cites] J Biol Chem. 1985 Jul 15;260(14):8262-71 [4008490.001]
  • [Cites] Biochemistry. 1985 Apr 9;24(8):1866-74 [3160388.001]
  • [Cites] J Natl Cancer Inst. 1985 Sep;75(3):447-54 [2863413.001]
  • [Cites] J Biol Chem. 1985 Dec 15;260(29):15510-5 [4066681.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):67-95 [10580130.001]
  • [Cites] J Soc Biol. 1999;193(1):85-99 [10851560.001]
  • [Cites] Gut. 2000 Aug;47(2):251-5 [10896917.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L181-7 [11133508.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 May;280(5):G1043-8 [11292614.001]
  • [Cites] Biochem J. 2001 Sep 15;358(Pt 3):657-64 [11577689.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):178-86 [11677243.001]
  • [Cites] Cancer Res. 1986 May;46(5):2627-32 [3516383.001]
  • [Cites] Cancer Res. 1986 Sep;46(9):4841-7 [3731131.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Cancer Res. 1988 Jul 1;48(13):3834-42 [3288336.001]
  • [Cites] J Biol Chem. 1988 Oct 15;263(29):15146-50 [2971663.001]
  • [Cites] Cancer Res. 1989 Feb 1;49(3):745-52 [2910493.001]
  • [Cites] J Biol Chem. 1991 Jan 25;266(3):1772-82 [1824844.001]
  • [Cites] Genomics. 1991 Oct;11(2):247-51 [1663069.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1199-211 [1312973.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1993 Jun;48(6):423-8 [8341719.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):415-24 [8020479.001]
  • [Cites] Glycobiology. 1994 Dec;4(6):873-84 [7734850.001]
  • [Cites] Glycobiology. 1995 May;5(3):351-7 [7655172.001]
  • [Cites] Eur J Biochem. 1995 Oct 15;233(2):607-17 [7588808.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2237-44 [8625291.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1354-67 [8613039.001]
  • [Cites] Cell Biol Int. 1997 May;21(5):281-7 [9243803.001]
  • [Cites] Biochemistry. 1998 Apr 7;37(14):4916-27 [9538010.001]
  • [Cites] Keio J Med. 1998 Mar;47(1):10-8 [9560527.001]
  • [Cites] Clin Exp Metastasis. 1998 Apr;16(3):267-74 [9568644.001]
  • [Cites] Biochemistry. 1999 May 25;38(21):6817-25 [10346903.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21209-16 [10409676.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):4083-9 [10463611.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12802-9 [11821425.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47724-31 [12361956.001]
  • (PMID = 15755813.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.- / UDP-GlcNAc GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase
  • [Other-IDs] NLM/ PMC555466
  •  go-up   go-down


24. Lauer-Fields J, Brew K, Whitehead JK, Li S, Hammer RP, Fields GB: Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors. J Am Chem Soc; 2007 Aug 29;129(34):10408-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alterations in activities of one family of proteases, the matrix metalloproteinases (MMPs), have been implicated in primary and metastatic tumor growth, angiogenesis, and pathological degradation of extracellular matrix (ECM) components, such as collagen and laminin.
  • The phosphinate triple-helical transition state analogue has high affinity and selectivity for the gelatinases (MMP-2 and MMP-9) and represents a new class of protease inhibitors that maximizes potential selectivity via interactions with both prime and nonprime active site subsites as well as with secondary binding sites (exosites).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Mar 30;404(6777):465-70 [10761907.001]
  • [Cites] Biochemistry. 2000 Apr 18;39(15):4543-51 [10758004.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4273-8 [10725403.001]
  • [Cites] Biochem Soc Trans. 2000;28(4):455-60 [10961939.001]
  • [Cites] J Med Chem. 2000 Sep 7;43(18):3377-85 [10978185.001]
  • [Cites] J Biol Chem. 2000 Sep 22;275(38):29610-7 [10871619.001]
  • [Cites] Biochemistry. 2000 Dec 5;39(48):14960-7 [11101312.001]
  • [Cites] J Comb Chem. 2000 Nov-Dec;2(6):624-38 [11138549.001]
  • [Cites] J Mol Biol. 2001 Mar 23;307(2):577-86 [11254383.001]
  • [Cites] Org Lett. 2001 Mar 8;3(5):659-62 [11259030.001]
  • [Cites] Biopolymers. 2000;55(6):436-50 [11304671.001]
  • [Cites] Biochemistry. 2001 May 15;40(19):5795-803 [11341845.001]
  • [Cites] Curr Med Chem. 2001 Jul;8(8):967-76 [11375764.001]
  • [Cites] J Org Chem. 2003 Feb 21;68(4):1575-8 [12585907.001]
  • [Cites] Chemistry. 2003 May 9;9(9):2079-94 [12740857.001]
  • [Cites] Biochemistry. 2004 Sep 14;43(36):11474-81 [15350133.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2788-95 [15353314.001]
  • [Cites] Anal Biochem. 1976 Jan;70(1):218-23 [176901.001]
  • [Cites] Biochemistry. 1987 Apr 7;26(7):1962-5 [3036215.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1987;52:83-90 [2841072.001]
  • [Cites] J Med Chem. 1990 Jan;33(1):263-73 [2153207.001]
  • [Cites] FEBS Lett. 1992 Jan 27;296(3):263-6 [1537400.001]
  • [Cites] Drugs. 1992 Jan;43(1):123-40 [1372856.001]
  • [Cites] Matrix Suppl. 1992;1:259-62 [1480035.001]
  • [Cites] J Cardiovasc Pharmacol. 1992;20 Suppl 10:S7-12 [1283429.001]
  • [Cites] Biopolymers. 1993 Nov;33(11):1695-707 [8241428.001]
  • [Cites] J Biol Chem. 1994 Aug 19;269(33):20952-7 [8063713.001]
  • [Cites] Bioorg Med Chem. 1993 Jul;1(1):19-26 [8081834.001]
  • [Cites] Biochem J. 1995 Jun 1;308 ( Pt 2):645-51 [7772054.001]
  • [Cites] FEBS Lett. 1996 Apr 15;384(2):155-61 [8612814.001]
  • [Cites] Biopolymers. 1996;40(4):345-57 [8765606.001]
  • [Cites] Biol Chem. 1998 Feb;379(2):185-91 [9524070.001]
  • [Cites] Biochem J. 1998 Apr 15;331 ( Pt 2):375-9 [9531473.001]
  • [Cites] Nature. 1998 Apr 16;392(6677):666-7 [9565027.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Jan 18;9(2):127-32 [10021913.001]
  • [Cites] Chem Biol. 1999 Feb;6(2):63-70 [10021421.001]
  • [Cites] Bioorg Med Chem. 1999 Feb;7(2):389-94 [10218833.001]
  • [Cites] J Med Chem. 1999 Jul 15;42(14):2610-20 [10411481.001]
  • [Cites] J Biomol Tech. 2004 Dec;15(4):305-16 [15585827.001]
  • [Cites] J Biol Chem. 2005 Jan 21;280(3):2370-7 [15533938.001]
  • [Cites] Curr Pharm Des. 2005;11(3):295-322 [15723627.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):385-92 [15781326.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):393-402 [15781327.001]
  • [Cites] Bioorg Med Chem. 2005 Aug 1;13(15):4740-9 [15935680.001]
  • [Cites] Org Lett. 2005 Sep 1;7(18):4049-52 [16119964.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):941-6 [16538215.001]
  • [Cites] J Biol Chem. 2006 Apr 21;281(16):11152-60 [16481329.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):17197-202 [16613845.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):785-99 [16955069.001]
  • [Cites] J Biol Chem. 2006 Dec 1;281(48):36937-43 [16998200.001]
  • [Cites] J Org Chem. 2007 Apr 13;72(8):3116-8 [17375960.001]
  • [Cites] J Org Chem. 2001 Oct 5;66(20):6604-10 [11578210.001]
  • [Cites] Biochemistry. 2001 Aug 14;40(32):9522-31 [11583151.001]
  • [Cites] FASEB J. 2002 Jan;16(1):93-5 [11709491.001]
  • [Cites] Biochemistry. 2002 May 14;41(19):6054-64 [11994000.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):657-72 [12209155.001]
  • [Cites] Biopolymers. 2002;66(1):19-32 [12228918.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):18140-5 [12642591.001]
  • [Cites] Bioorg Med Chem Lett. 2003 Jul 21;13(14):2331-6 [12824028.001]
  • [Cites] Biochem J. 2004 Feb 1;377(Pt 3):775-9 [14533979.001]
  • [Cites] Protein Sci. 2004 Apr;13(4):893-902 [15010541.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):166-73 [15113693.001]
  • [Cites] J Am Chem Soc. 2004 Jul 14;126(27):8388-9 [15237990.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10000-5 [15220480.001]
  • [Cites] EMBO J. 2004 Aug 4;23(15):3020-30 [15257288.001]
  • (PMID = 17672455.001).
  • [ISSN] 0002-7863
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098799-06; United States / NCI NIH HHS / CA / R01 CA098799; United States / NCI NIH HHS / CA / CA 98799; United States / NCI NIH HHS / CA / R01 CA098799-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / Protease Inhibitors; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ NIHMS62617; NLM/ PMC2531068
  •  go-up   go-down


25. Garamszegi N, Garamszegi SP, Shehadeh LA, Scully SP: Extracellular matrix-induced gene expression in human breast cancer cells. Mol Cancer Res; 2009 Mar;7(3):319-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracellular matrix-induced gene expression in human breast cancer cells.
  • It was previously unknown whether the same molecules acting as soluble peptides could generate signal cascades without the associated mechanical anchoring, a condition that may be encountered during matrix remodeling and degradation and relevant to invasion and metastatic processes.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • [Cites] Mol Biol Cell. 1998 Sep;9(9):2627-38 [9725916.001]
  • [Cites] Nat Cell Biol. 2003 May;5(5):410-21 [12717440.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Osteoarthritis Cartilage. 2003 Aug;11(8):603-12 [12880583.001]
  • [Cites] Matrix Biol. 1999 Aug;18(4):331-41 [10517180.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):23549-58 [15843372.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):675-88 [16148884.001]
  • [Cites] PLoS Comput Biol. 2006 Jan;2(1):e3 [16446785.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):392-401 [16572188.001]
  • [Cites] Circ Res. 2006 Apr 28;98(8):1032-9 [16556868.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1311-9 [16622460.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:343-56 [16869771.001]
  • [Cites] J Investig Dermatol Symp Proc. 2006 Sep;11(1):73-8 [17069013.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11228-37 [17145868.001]
  • [Cites] Nat Methods. 2007 Apr;4(4):359-65 [17396127.001]
  • [Cites] Cell Res. 2007 Apr;17(4):289-90 [17426696.001]
  • [Cites] Front Biosci. 2007;12:3468-74 [17485314.001]
  • [Cites] J Cell Biol. 2007 Jul 30;178(3):437-51 [17646396.001]
  • [Cites] Anal Biochem. 2007 Oct 1;369(1):41-53 [17570334.001]
  • [Cites] Stem Cell Rev. 2007 Jun;3(2):137-46 [17873346.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Nov;8(11):857-69 [17895899.001]
  • [Cites] J Cell Sci. 2008 Apr 1;121(Pt 7):1036-45 [18334556.001]
  • [Cites] J Clin Invest. 2008 Apr;118(4):1367-79 [18340378.001]
  • [Cites] Cell. 2008 Jul 25;134(2):215-30 [18662538.001]
  • [Cites] Cell. 1999 Feb 5;96(3):319-28 [10025398.001]
  • [Cites] Bone. 2000 Mar;26(3):241-7 [10709996.001]
  • [Cites] Genes Dev. 2000 Mar 15;14(6):627-44 [10733523.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21785-8 [10801897.001]
  • [Cites] J Immunol Methods. 2001 Jan 1;247(1-2):25-34 [11150534.001]
  • [Cites] Mol Biol Cell. 2001 Mar;12(3):675-84 [11251079.001]
  • [Cites] Chest. 2001 Jul;120(1 Suppl):49S-53S [11451914.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):584-92 [11544027.001]
  • [Cites] Mol Biol Cell. 2001 Sep;12(9):2881-93 [11553725.001]
  • [Cites] Immunol Lett. 2002 Jun 3;82(1-2):85-91 [12008039.001]
  • [Cites] Science. 2002 May 31;296(5573):1646-7 [12040180.001]
  • [Cites] Mol Cell Biol. 2002 Jul;22(13):4750-9 [12052882.001]
  • [Cites] Mol Pharmacol. 2002 Jul;62(1):65-74 [12065756.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1551-9 [12070302.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):565-71 [14519391.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Breast Cancer Res. 2004;6(1):1-11 [14680479.001]
  • [Cites] FASEB J. 2004 Feb;18(2):364-6 [14688206.001]
  • [Cites] Cell Signal. 2004 Oct;16(10):1133-40 [15240008.001]
  • [Cites] J Leukoc Biol. 1993 Apr;53(4):354-65 [8482915.001]
  • [Cites] J Cell Biol. 1997 Jun 16;137(6):1445-57 [9182674.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):537-46 [12492495.001]
  • (PMID = 19276183.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA096796-01A2; United States / NHLBI NIH HHS / HL / F32 HL083673-01; United States / NHLBI NIH HHS / HL / 1 F32 HL083673-01; United States / NCI NIH HHS / CA / CA096796-01A2; United States / NHLBI NIH HHS / HL / HL083673-01; United States / NCI NIH HHS / CA / R01 CA096796; United States / NCI NIH HHS / CA / CA096796-01; United States / NHLBI NIH HHS / HL / F32 HL083673
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Collagen Type I; 0 / Collagen Type II; 0 / Fibronectins; 0 / Integrin alpha2beta1; 0 / Laminin; 0 / SMAD2 protein, human; 0 / SMAD4 protein, human; 0 / Smad2 Protein; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ NIHMS100973; NLM/ PMC2681181
  •  go-up   go-down


31. Aizawa J, Sakayama K, Kamei S, Kidani T, Yamamoto H, Norimatsu Y, Masuno H: Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8. BMC Cancer; 2010;10:51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The TGZ group had less metastatic tumors in the lung compared with the control group.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 1999 Oct 21;9(20):R776-8 [10531025.001]
  • [Cites] Int J Cancer. 2009 Dec 1;125(11):2576-85 [19551863.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):589-93 [11212254.001]
  • [Cites] Cancer Invest. 2001;19(3):292-315 [11338887.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7647-53 [11606407.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):1123-7 [11798192.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1466-75 [11920503.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):344-51 [11920584.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1288-94 [12006550.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):1-9 [12538445.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2172-8 [12727836.001]
  • [Cites] Toxicol Sci. 2003 Oct;75(2):314-20 [12883076.001]
  • [Cites] J Orthop Res. 2004 Nov;22(6):1168-74 [15475193.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):7022-30 [15501982.001]
  • [Cites] Anal Biochem. 1971 Jan;39(1):197-201 [5544593.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 May;82(10):3262-6 [2860667.001]
  • [Cites] Arch Pathol Lab Med. 1987 Sep;111(9):841-5 [2888448.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Cell. 1996 Nov 1;87(3):377-89 [8898192.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:335-63 [8970730.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2474-84 [9059336.001]
  • [Cites] Int J Cancer. 1998 May 4;76(3):418-22 [9579581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] Diabet Med. 1999 Mar;16(3):179-92 [10227562.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S42-51 [10357558.001]
  • [Cites] Br J Pharmacol. 2004 Dec;143(8):933-7 [15533890.001]
  • [Cites] Toxicol Sci. 2005 Apr;84(2):319-27 [15659569.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):847-52 [16142341.001]
  • [Cites] BMC Cancer. 2006;6:53 [16519808.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):702-13 [17096328.001]
  • [Cites] BMC Cancer. 2007;7:216 [18021457.001]
  • [Cites] BMC Cancer. 2008;8:47 [18261208.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:69 [19014499.001]
  • [Cites] Cancer Sci. 2009 Apr;100(4):770-7 [19469020.001]
  • [Cites] J Orthop Res. 2009 Jul;27(7):909-15 [19105229.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):572-7 [10690541.001]
  • (PMID = 20170548.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Chromans; 0 / Hypoglycemic Agents; 0 / Thiazolidinediones; EC 3.4.24.24 / Matrix Metalloproteinase 2; I66ZZ0ZN0E / troglitazone
  • [Other-IDs] NLM/ PMC2838820
  •  go-up   go-down


32. Baek WS, Kubba SV: Cauda equina syndrome due to leptomeningeal carcinomatosis of the ovary. Gynecol Oncol; 2008 Dec;111(3):544-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On exam she had decreased anal tone with saddle anesthesia.
  • CSF showed malignant cells consistent with metastatic ovarian adenocarcinoma.
  • CONCLUSION: Ovarian cancer metastasizng to the cauda equina should be highly suspected based on the clinical presentation alone, even with unremarkable imaging studies.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Meningeal Carcinomatosis / pathology. Ovarian Neoplasms / pathology. Polyradiculopathy / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433846.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


34. Rutkowski P, Nowecki ZI, van Akkooi AC, Kulik J, Wanda M, Siedlecki JA, Eggermont AM, Ruka W: Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden. Ann Surg Oncol; 2010 Dec;17(12):3314-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: According to univariate analysis, the following factors had a negative impact on overall survival (OS): higher Breslow thickness (P = .0001), ulceration (P < .0001), higher Clark level (P = .008), male gender (P = .0001), metastatic lymph nodes >1 (P < .0001), nodal metastases extracapsular extension (P < .0001), metastases to additional non-SNs (P = .0004), micrometastases size ≥ 0.1 mm (P = .0006), and positive LY MM-RT-PCR (P = .0007).

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2008 Sep;159(3):597-605 [18616789.001]
  • [Cites] Ann Surg Oncol. 2004 Sep;11(9):829-36 [15313732.001]
  • [Cites] Ann Surg. 2008 Dec;248(6):949-55 [19092339.001]
  • [Cites] Ann Surg Oncol. 2009 Jan;16(1):177-85 [18982394.001]
  • [Cites] Ann Surg Oncol. 2009 Jul;16(7):2018-27 [19132446.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Lancet. 1991 Nov 16;338(8777):1227-9 [1719320.001]
  • [Cites] Semin Surg Oncol. 1998 Jun;14(4):291-301 [9588722.001]
  • [Cites] JAMA. 1998 Oct 28;280(16):1410-5 [9801000.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):976-83 [10071292.001]
  • [Cites] Br J Dermatol. 1999 Jul;141(1):30-6 [10417512.001]
  • [Cites] Ann Surg Oncol. 2004 Nov;11(11):988-97 [15525828.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1218-27 [15718319.001]
  • [Cites] Lancet. 2005 Oct 1;366(9492):1189-96 [16198768.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9427; author reply 9428 [16361644.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):372-80 [16403622.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2849-57 [16782924.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1578-85 [16968875.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1307-17 [17005948.001]
  • [Cites] N Engl J Med. 2006 Sep 28;355(13):1370-1 [17005955.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):906-12 [17136471.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1588-95 [17443001.001]
  • [Cites] Melanoma Res. 2007 Apr;17(2):83-9 [17496783.001]
  • [Cites] Melanoma Res. 2008 Aug;18(4):246-52 [18626308.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2223-34 [18506535.001]
  • [Cites] J Clin Oncol. 2008 Sep 10;26(26):4296-303 [18606982.001]
  • [Cites] Ann Surg Oncol. 2009 Aug;16(8):2245-51 [19517194.001]
  • [Cites] Ann Oncol. 2009 Aug;20 Suppl 6:vi22-9 [19617294.001]
  • [Cites] Tumori. 2009 May-Jun;95(3):298-302 [19688967.001]
  • [Cites] Ann Surg Oncol. 2009 Nov;16(11):2978-84 [19711133.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6199-206 [19917835.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2562-71 [10561323.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2253-7 [10786692.001]
  • [Cites] Clin Chem. 2001 Mar;47(3):505-12 [11238304.001]
  • [Cites] Melanoma Res. 2001 Feb;11(1):65-73 [11254117.001]
  • [Cites] Arch Dermatol. 2001 Mar;137(3):325-30 [11255333.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2401-8 [11413531.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3622-34 [11504744.001]
  • [Cites] Melanoma Res. 2002 Aug;12(4):399-401 [12170191.001]
  • [Cites] Melanoma Res. 2003 Feb;13(1):35-43 [12569283.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):767-73 [12610172.001]
  • [Cites] J Pathol. 2003 Jul;200(3):314-9 [12845627.001]
  • [Cites] Clin Chem. 2003 Sep;49(9):1450-7 [12928225.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3566-72 [12913098.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1457-62 [14562017.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1605-12 [15014010.001]
  • [Cites] J Surg Oncol. 2004 Jul 1;86(4):212-23 [15221928.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3345-9 [15310779.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5742-7 [18981467.001]
  • (PMID = 20607422.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MAGEA1 protein, human; 0 / MART-1 Antigen; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 1.14.18.1 / Monophenol Monooxygenase
  • [Other-IDs] NLM/ PMC2995879
  •  go-up   go-down


35. Meyer A, Bruns F, Richter K, Grünwald V, Karstens JH: Small cell cancer of the anal canal--case report of a rare tumor. Anticancer Res; 2007 Mar-Apr;27(2):1047-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell cancer of the anal canal--case report of a rare tumor.
  • BACKGROUND: We report on a rare case of small cell cancer located at the anal canal.
  • CASE REPORT: A 41-year old woman presented with locally advanced small cell anal cancer and simultaneous hepatic and pulmonal deposits.
  • Due to metastatic disease, chemotherapy with etoposide and cisplatin was performed with mixed response after four cycles of chemotherapy.
  • CONCLUSION: In patients with metastatic small cell anal cancer chemotherapy remains the mainstay of therapy.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / therapy. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465242.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


36. Xu HN, Nioka S, Glickson JD, Chance B, Li LZ: Quantitative mitochondrial redox imaging of breast cancer metastatic potential. J Biomed Opt; 2010 May-Jun;15(3):036010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative mitochondrial redox imaging of breast cancer metastatic potential.
  • Predicting tumor metastatic potential remains a challenge in cancer research and clinical practice.
  • Our goal was to identify novel biomarkers for differentiating human breast tumors with different metastatic potentials by imaging the in vivo mitochondrial redox states of tumor tissues.
  • The more metastatic (aggressive) MDA-MB-231 and less metastatic (indolent) MCF-7 human breast cancer mouse xenografts were imaged with the low-temperature redox scanner to obtain multi-slice fluorescence images of reduced nicotinamide adenine dinucleotide (NADH) and oxidized flavoproteins (Fp).
  • Mitochondrial redox imaging can be clinically implemented utilizing cryogenic biopsy specimens and is useful for drug development and for clinical diagnosis of breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1968 Jun 28;31(6):895-900 [4299232.001]
  • [Cites] Cell Metab. 2008 Jan;7(1):11-20 [18177721.001]
  • [Cites] Science. 1977 Aug 26;197(4306):893-5 [887927.001]
  • [Cites] J Biol Chem. 1979 Jun 10;254(11):4764-71 [220260.001]
  • [Cites] J Biol Chem. 1982 May 25;257(10):5476-81 [7068601.001]
  • [Cites] Science. 1982 Sep 10;217(4564):998-1003 [7112116.001]
  • [Cites] J Natl Cancer Inst. 1984 Apr;72(4):913-7 [6584666.001]
  • [Cites] Cancer Res. 1984 Jun;44(6):2259-65 [6372991.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5702-6 [6498833.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4716-22 [11406542.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] Biochem J. 2002 May 15;364(Pt 1):309-15 [11988105.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):453-8 [12778135.001]
  • [Cites] Bioconjug Chem. 2003 Jul-Aug;14(4):709-14 [12862422.001]
  • [Cites] Nucl Med Biol. 2004 Aug;31(6):761-70 [15246367.001]
  • [Cites] J Biomed Opt. 2004 Jul-Aug;9(4):772-8 [15250765.001]
  • [Cites] Science. 2008 May 2;320(5876):661-4 [18388260.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:96S-112S [18523068.001]
  • [Cites] Mitochondrion. 2008 Sep;8(4):339-44 [18727959.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1298-306 [19028270.001]
  • [Cites] Adv Exp Med Biol. 2009;645:247-53 [19227478.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2588-93 [19351761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6608-13 [19366661.001]
  • [Cites] Science. 2009 May 22;324(5930):1029-33 [19460998.001]
  • [Cites] Science. 1952 Aug 22;116(3008):200-2 [17792313.001]
  • [Cites] Anal Biochem. 1985 Aug 1;148(2):389-400 [4061818.001]
  • [Cites] Adv Exp Med Biol. 1973;37A:277-92 [4378058.001]
  • [Cites] Biotechniques. 1990 Sep;9(3):324-31 [2223075.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 5;84(3):165-74 [1371813.001]
  • [Cites] FASEB J. 1995 May;9(8):651-8 [7768357.001]
  • [Cites] Clin Exp Metastasis. 1997 Jan;15(1):53-62 [9009106.001]
  • [Cites] Nat Med. 1997 Feb;3(2):177-82 [9018236.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):507-25 [9034607.001]
  • [Cites] Int Rev Cytol. 1998;177:1-56 [9378615.001]
  • [Cites] Ann N Y Acad Sci. 1997 Dec 29;833:137-46 [9616746.001]
  • [Cites] Mutat Res. 1998 Feb 26;398(1-2):19-26 [9626961.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Nature. 1955 Aug 6;176(4475):250-4 [13244669.001]
  • [Cites] J Biol Chem. 1958 Sep;233(3):736-9 [13575447.001]
  • [Cites] Science. 1959 Mar 13;129(3350):700-8 [13635004.001]
  • [Cites] Science. 1962 Aug 17;137(3529):499-508 [13878016.001]
  • [Cites] J Biol Chem. 1955 Nov;217(1):429-38 [13271405.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] J Clin Oncol. 2005 Mar 10;23(8):1664-73 [15755974.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):125-6 [15725722.001]
  • [Cites] J Control Release. 2005 Dec 5;109(1-3):222-35 [16290245.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):8927-30 [16982728.001]
  • [Cites] J Fluoresc. 2007 Jan;17(1):37-42 [17171438.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C125-36 [16971499.001]
  • [Cites] FEBS J. 2007 Mar;274(6):1393-418 [17302740.001]
  • [Cites] Neoplasia. 2007 May;9(5):382-91 [17534443.001]
  • [Cites] Antioxid Redox Signal. 2007 Aug;9(8):1221-35 [17536958.001]
  • [Cites] J Bioenerg Biomembr. 2007 Jun;39(3):267-74 [17551814.001]
  • [Cites] Circ Res. 1976 May;38(5 Suppl 1):I31-8 [178460.001]
  • (PMID = 20615012.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA083105; United States / NCI NIH HHS / CA / U01 CA105490; United States / NCRR NIH HHS / RR / RR02305; United States / NCI NIH HHS / CA / UO1-CA105490; United States / NCI NIH HHS / CA / U54 CA105008; United States / NCRR NIH HHS / RR / P41 RR002305; United States / NCI NIH HHS / CA / 2U24-CA083105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; 0 / Flavoproteins; 0U46U6E8UK / NAD
  • [Other-IDs] NLM/ PMC3188620
  •  go-up   go-down


37. Xu Y, Phillips JA, Yan J, Li Q, Fan ZH, Tan W: Aptamer-based microfluidic device for enrichment, sorting, and detection of multiple cancer cells. Anal Chem; 2009 Sep 1;81(17):7436-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aptamer-based microfluidic device for enrichment, sorting, and detection of multiple cancer cells.
  • The ability to diagnose cancer based on the detection of rare cancer cells in blood or other bodily fluids is a significant challenge.
  • To address this challenge, we have developed a microfluidic device that can simultaneously sort, enrich, and then detect multiple types of cancer cells from a complex sample.
  • Enrichment and detection of multiple rare cancer cells can be used to detect cancers at the early stages, diagnose metastatic relapse, stratify patients for therapeutic purposes, monitor response to drugs and therapies, track tumor progression, and gain a deeper understanding of the biology of circulating tumor cells (CTCs).

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):274-84 [19308067.001]
  • [Cites] Anal Chem. 2009 Feb 1;81(3):1033-9 [19115856.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2912-8 [19339269.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):577-82 [11304694.001]
  • [Cites] Biotechnol Prog. 2003 May-Jun;19(3):899-907 [12790655.001]
  • [Cites] Anal Chem. 2004 Apr 1;76(7):1824-31 [15053639.001]
  • [Cites] N Engl J Med. 2004 Aug 19;351(8):781-91 [15317891.001]
  • [Cites] Biotechnol Appl Biochem. 2004 Oct;40(Pt 2):145-9 [14670084.001]
  • [Cites] Lab Chip. 2004 Oct;4(5):464-72 [15472730.001]
  • [Cites] Exp Hematol. 2004 Oct;32(10):891-904 [15504544.001]
  • [Cites] Cancer Res. 1975 Mar;35(3):512-6 [1090362.001]
  • [Cites] Cancer Res. 1976 Mar;36(3):889-94 [1253177.001]
  • [Cites] Immunotechnology. 1998 Oct;4(2):89-96 [9853950.001]
  • [Cites] J Immunol Methods. 1999 Mar 4;223(2):195-205 [10089098.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15861-6 [15514025.001]
  • [Cites] Lab Chip. 2004 Dec;4(6):614-8 [15570374.001]
  • [Cites] Langmuir. 2004 Dec 21;20(26):11649-55 [15595794.001]
  • [Cites] Biotechnol Bioeng. 2005 Sep 30;91(7):816-26 [16037988.001]
  • [Cites] Biosens Bioelectron. 2006 Apr 15;21(10):1991-5 [16242927.001]
  • [Cites] Anal Chem. 2006 May 1;78(9):3084-9 [16642997.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11838-43 [16873550.001]
  • [Cites] Biomol Eng. 2006 Oct;23(5):213-31 [16905357.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] Lab Chip. 2007 Feb;7(2):170-8 [17268618.001]
  • [Cites] Anal Chem. 2007 Apr 15;79(8):3075-82 [17348633.001]
  • [Cites] Nat Rev Genet. 2007 May;8(5):341-52 [17440531.001]
  • [Cites] Clin Chem. 2007 Jun;53(6):1153-5 [17463173.001]
  • [Cites] Anal Chem. 2007 Jul 1;79(13):4900-7 [17530817.001]
  • [Cites] Int J Nanomedicine. 2006;1(1):3-14 [17722258.001]
  • [Cites] Biomol Eng. 2007 Oct;24(4):381-403 [17627883.001]
  • [Cites] Mol Ther. 2008 Jan;16(1):66-73 [17912235.001]
  • [Cites] Nature. 2007 Dec 20;450(7173):1235-9 [18097410.001]
  • [Cites] Anal Chem. 2008 Feb 1;80(3):721-8 [18177018.001]
  • [Cites] Cancer Res. 2008 Apr 1;68(7):2358-65 [18381443.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):329-40 [18404148.001]
  • [Cites] ChemMedChem. 2008 Jun;3(6):991-1001 [18338423.001]
  • [Cites] J Am Chem Soc. 2008 Jul 9;130(27):8633-41 [18557614.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):366-77 [18596266.001]
  • [Cites] Langmuir. 2008 Oct 21;24(20):11860-5 [18817428.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):7004-10 [18980996.001]
  • [Cites] N Engl J Med. 2008 Dec 25;359(26):2814-23 [19109576.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Apr;6(4):190-1 [19333222.001]
  • (PMID = 19715365.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] None / None / / R21 CA122648-01A1; United States / NCI NIH HHS / CA / R21 CA122648; None / None / / R21 CA122648-02S1; None / None / / R21 CA122648-02; United States / NCI NIH HHS / CA / R21 CA122648-02S1; United States / NCI NIH HHS / CA / R21 CA122648-01A1; United States / NCI NIH HHS / CA / R21 CA122648-02
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide
  • [Other-IDs] NLM/ NIHMS136194; NLM/ PMC3164879
  •  go-up   go-down


38. Venkatesh SK, Yin M, Glockner JF, Takahashi N, Araoz PA, Talwalkar JA, Ehman RL: MR elastography of liver tumors: preliminary results. AJR Am J Roentgenol; 2008 Jun;190(6):1534-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Forty-four liver tumors (14 metastatic lesions, 12 hepatocellular carcinomas, nine hemangiomas, five cholangiocarcinomas, three cases of focal nodular hyperplasia, and one hepatic adenoma) were evaluated with MRE.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Magn Reson Imaging. 2001 Jul;14(1):63-71 [11436216.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1207-1213.e2 [17916548.001]
  • [Cites] Med Image Anal. 2001 Dec;5(4):237-54 [11731304.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jun;178(6):1411-7 [12034608.001]
  • [Cites] Clin Radiol. 2002 Nov;57(11):1014-20 [12409113.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):803-11 [12942086.001]
  • [Cites] Med Image Anal. 2003 Dec;7(4):465-73 [14561551.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] Ultrason Imaging. 1991 Apr;13(2):111-34 [1858217.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1854-7 [7569924.001]
  • [Cites] Radiology. 1996 Mar;198(3):920-6 [8628896.001]
  • [Cites] Nat Med. 1996 May;2(5):601-3 [8616724.001]
  • [Cites] Radiology. 1997 Jan;202(1):79-86 [8988195.001]
  • [Cites] Magn Reson Imaging. 2005 Feb;23(2):159-65 [15833607.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Oct;9(4):325-42 [15838603.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):241-54 [16169468.001]
  • [Cites] Radiology. 2005 Oct;237(1):202-11 [16118150.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] NMR Biomed. 2006 Apr;19(2):173-9 [16521091.001]
  • [Cites] Radiology. 2006 Aug;240(2):440-8 [16864671.001]
  • [Cites] Radiology. 2007 Apr;243(1):258-67 [17293571.001]
  • [Cites] Acta Radiol. 2007 Apr;48(3):327-30 [17453505.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S49-60 [17486052.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • (PMID = 18492904.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB001981-07; United States / NIBIB NIH HHS / EB / R01 EB001981-08; United States / NIBIB NIH HHS / EB / R01 EB001981; United States / NIBIB NIH HHS / EB / EB001981; United States / NIBIB NIH HHS / EB / R01 EB001981-07; United States / NIBIB NIH HHS / EB / EB001981-08
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS196000; NLM/ PMC2894569
  •  go-up   go-down


39. Madhok BM, Yeluri S, Perry SL, Hughes TA, Jayne DG: Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells. Br J Cancer; 2010 Jun 8;102(12):1746-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dichloroacetate induces apoptosis and cell-cycle arrest in colorectal cancer cells.
  • BACKGROUND: Cancer cells are highly dependent on glycolysis.
  • Our aim was to determine if switching metabolism from glycolysis towards mitochondrial respiration would reduce growth preferentially in colorectal cancer cells over normal cells, and to examine the underlying mechanisms.
  • METHODS: Representative colorectal cancer and non-cancerous cell lines were treated with dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase.
  • RESULTS: Dichloroacetate (20 mM) did not reduce growth of non-cancerous cells but caused significant decrease in cancer cell proliferation (P=0.009), which was associated with apoptosis and G(2) phase cell-cycle arrest.
  • The largest apoptotic effect was evident in metastatic LoVo cells, in which DCA induced up to a ten-fold increase in apoptotic cell counts after 48 h.
  • Dichloroacetate reduced lactate levels in growth media and induced dephosphorylation of E1alpha subunit of pyruvate dehydrogenase complex in all cell lines, but the intrinsic mitochondrial membrane potential was reduced in only cancer cells (P=0.04).
  • CONCLUSIONS: Pyruvate dehydrogenase kinase inhibition attenuates glycolysis and facilitates mitochondrial oxidative phosphorylation, leading to reduced growth of colorectal cancer cells but not of non-cancerous cells.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. OXYGEN .
  • Hazardous Substances Data Bank. DICHLOROACETIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):891-9 [15516961.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C125-36 [16971499.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):37-51 [17222789.001]
  • [Cites] Sci STKE. 2007 Apr 10;2007(381):pe14 [17426345.001]
  • [Cites] J Bioenerg Biomembr. 2007 Jun;39(3):251-7 [17624581.001]
  • [Cites] Gynecol Oncol. 2008 Jun;109(3):394-402 [18423823.001]
  • [Cites] Prostate. 2008 Aug 1;68(11):1223-31 [18465755.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):989-94 [18766181.001]
  • [Cites] Int J Colorectal Dis. 2008 Nov;23(11):1049-55 [18594846.001]
  • [Cites] Gut. 2009 Mar;58(3):404-12 [18978174.001]
  • [Cites] Anal Biochem. 2009 Jun 15;389(2):157-64 [19341700.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Jul;135(7):867-77 [19415328.001]
  • [Cites] Electrophoresis. 2009 Jun;30(12):2182-92 [19582719.001]
  • [Cites] Eur J Surg Oncol. 2009 Dec;35(12):1286-94 [19540709.001]
  • [Cites] Breast Cancer Res Treat. 2010 Feb;120(1):253-60 [19543830.001]
  • [Cites] J Clin Pharmacol. 2003 Jul;43(7):683-91 [12856382.001]
  • [Cites] Semin Radiat Oncol. 2004 Jul;14(3):249-58 [15254868.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):91-9 [2745213.001]
  • [Cites] Metabolism. 1989 Nov;38(11):1124-44 [2554095.001]
  • [Cites] Bull World Health Organ. 1990;68(3):377-85 [2203551.001]
  • [Cites] FEBS Lett. 1997 Jan 2;400(1):127-30 [9000527.001]
  • [Cites] Biochem J. 1998 Jan 1;329 ( Pt 1):191-6 [9405293.001]
  • [Cites] Environ Health Perspect. 1998 Aug;106 Suppl 4:989-94 [9703483.001]
  • [Cites] Mol Cell Proteomics. 2006 Jun;5(6):1119-30 [16554294.001]
  • (PMID = 20485289.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 33X04XA5AT / Lactic Acid; 9LSH52S3LQ / Dichloroacetic Acid; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.2 / pyruvate dehydrogenase (acetyl-transferring) kinase; S88TT14065 / Oxygen
  • [Other-IDs] NLM/ PMC2883702
  •  go-up   go-down


40. Tuomela J, Valta M, Seppänen J, Tarkkonen K, Väänänen HK, Härkönen P: Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. BMC Cancer; 2009;9:362
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors.
  • BACKGROUND: Prostate cancer metastasizes to regional lymph nodes and distant sites but the roles of lymphatic and hematogenous pathways in metastasis are not fully understood.
  • METHODS: We studied the roles of VEGF-C and VEGFR3 in prostate cancer metastasis by blocking VEGFR3 using intravenous adenovirus-delivered VEGFR3-Ig fusion protein (VEGFR3-Ig) and by ectopic expression of VEGF-C in PC-3 prostate tumors in nude mice.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Jun 5;94(11):819-25 [12048269.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1883-6 [11976409.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8868-73 [12070340.001]
  • [Cites] FASEB J. 2002 Jul;16(9):922-34 [12087053.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):573-83 [12154350.001]
  • [Cites] J Urol. 2003 Mar;169(3):849-54 [12576797.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):167-77 [12883995.001]
  • [Cites] Nat Immunol. 2004 Jan;5(1):74-80 [14634646.001]
  • [Cites] Prostate. 2004 Feb 1;58(2):193-9 [14716745.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):695 [14973470.001]
  • [Cites] Biochim Biophys Acta. 2004 Mar 4;1654(1):3-12 [14984763.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4400-4 [15231646.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5137-44 [15297417.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Nov 12;324(2):909-15 [15474514.001]
  • [Cites] Cancer Res. 1975 Dec;35(12):3698-704 [1192428.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):977-81 [10551327.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2406-12 [10590384.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):672-82 [11179212.001]
  • [Cites] Nat Med. 2001 Feb;7(2):192-8 [11175850.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1786-90 [11280723.001]
  • [Cites] Trends Immunol. 2001 Jun;22(6):317-21 [11377291.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4762-73 [11532940.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):893-903 [11549582.001]
  • [Cites] Int J Cancer. 2002 Apr 20;98(6):946-51 [11948478.001]
  • [Cites] Urology. 1983 Apr;21(4):337-44 [6340324.001]
  • [Cites] J Urol. 1983 Aug;130(2):290-2 [6876275.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 17;84(12):951-7 [1378502.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1751 [8612600.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3898-911 [9233800.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):309-13 [10390013.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):143-52 [15297858.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 5;97(1):14-21 [15632376.001]
  • [Cites] Cardiovasc Res. 2005 Feb 15;65(3):550-63 [15664381.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):584-93 [15701844.001]
  • [Cites] Breast Cancer Res Treat. 2005 May;91(2):125-32 [15868440.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4739-46 [15930292.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6901-9 [16061674.001]
  • [Cites] Prostate. 2005 Oct 1;65(2):110-6 [15880525.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9789-98 [16267000.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9566-75 [17018613.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s [17062708.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):593-9 [17234768.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1010-7 [17032920.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]
  • [Cites] BMC Cancer. 2008;8:81 [18371232.001]
  • [Cites] Nature. 2008 Jul 31;454(7204):656-60 [18594512.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] J Cell Biochem. 2009 Jul 1;107(4):769-84 [19415685.001]
  • (PMID = 19821979.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C
  • [Other-IDs] NLM/ PMC2767356
  •  go-up   go-down


41. Karanikolas BD, Figueiredo ML, Wu L: Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate; 2010 May 1;70(6):675-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
  • Polycomb Group protein enhancer of zeste 2 (EZH2) was found to be overexpressed in metastatic prostate tumors, and is considered an excellent candidate for such a biomarker.
  • METHODS: In this study, a comprehensive evaluation of the phenotypic effects of EZH2 in a panel of five prostate cancer cell lines was performed.
  • By using multiple cell lines, and examining overexpression and knockdown of EZH2 concurrently, a broad view of EZH2's role in prostate cancer was achieved.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BJU Int. 2000 May;85(7):932-44 [10792179.001]
  • [Cites] Mol Cancer Res. 2009 Sep;7(9):1456-65 [19723877.001]
  • [Cites] Genes Dev. 2000 Oct 1;14(19):2410-34 [11018010.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):551-7 [11208850.001]
  • [Cites] Curr Opin Genet Dev. 2001 Apr;11(2):175-81 [11250141.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):377-82 [11752410.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2728-43 [12857860.001]
  • [Cites] Hum Gene Ther. 2003 Aug 10;14(12):1207-12 [12908971.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):481-8 [14965441.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4930-7 [15077161.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):57-67 [15225548.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4061-71 [15385962.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Natl Cancer Inst Monogr. 1978 Dec;(49):17-21 [571045.001]
  • [Cites] Invest Urol. 1979 Jul;17(1):16-23 [447482.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(3):148-54 [2544306.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1721-32 [7906858.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6049-52 [7525052.001]
  • [Cites] Nucleic Acids Res. 1995 Feb 25;23(4):628-33 [7899083.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):5007-15 [9030563.001]
  • [Cites] Nat Med. 1997 Apr;3(4):402-8 [9095173.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3219-32 [9214638.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3586-95 [9584199.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9 [10462204.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9209-16 [15604294.001]
  • [Cites] Curr Biol. 2005 May 24;15(10):942-7 [15916951.001]
  • [Cites] Science. 2005 Oct 14;310(5746):306-10 [16224021.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7465-74 [16288293.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] Nature. 2006 Feb 16;439(7078):871-4 [16357870.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1168-74 [16489070.001]
  • [Cites] Cell. 2006 May 5;125(3):467-81 [16603238.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):639-45 [16575874.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):494-504 [16844419.001]
  • [Cites] Genes Dev. 2007 Jan 1;21(1):49-54 [17210787.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):547-56 [17252556.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5097-102 [17545586.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6579-84 [18006757.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):595-602 [17943722.001]
  • [Cites] Prostate. 2008 Jan 1;68(1):78-84 [18008331.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):205-9 [18223322.001]
  • [Cites] PLoS Comput Biol. 2008 Feb;4(2):e28 [18282083.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] Nature. 2000 Aug 10;406(6796):593-9 [10949293.001]
  • (PMID = 20087897.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI028697-17; United States / NCI NIH HHS / CA / CA092131-080007; United States / NIAID NIH HHS / AI / P30 AI028697-17; United States / NCI NIH HHS / CA / P50 CA092131; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA101904-07; United States / NCI NIH HHS / CA / P30 CA016042-34; United States / NCI NIH HHS / CA / R01 CA101904; United States / NCI NIH HHS / CA / P50 CA092131-080007; United States / NCI NIH HHS / CA / CA016042-34; United States / NCI NIH HHS / CA / CA101904-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Transcription Factors; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2
  • [Other-IDs] NLM/ NIHMS179057; NLM/ PMC2848714
  •  go-up   go-down


42. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, Park PJ, McKinney M: Pathway analysis of primary central nervous system lymphoma. Blood; 2008 Mar 15;111(6):3200-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The alterations in gene expression can be interpreted within several biologic contexts with implications for PCNSL, including CNS tropism (ECM and adhesion-related pathways, SPP1, DDR1), B-cell migration (CXCL13, SPP1), activated B-cell subtype (MUM1), lymphoproliferation (SPP1, TCL1A, CHI3L1), aggressive clinical behavior (SPP1, CHI3L1, MUM1), and aggressive metastatic cancer phenotype (SPP1, CHI3L1).

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2000 Dec;47(6):1400-9 [11126911.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):520-5 [11395428.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1731-5 [11721059.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Bioinformatics. 2002 Aug;18(8):1054-63 [12176828.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2507-15 [12193720.001]
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1063-9 [12631608.001]
  • [Cites] Brain. 2003 May;126(Pt 5):1058-67 [12690046.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Mol Carcinog. 2004 May;40(1):47-61 [15108329.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3029-34 [15131039.001]
  • [Cites] Anal Biochem. 2004 Aug 15;331(2):243-54 [15265729.001]
  • [Cites] Lancet. 1983 Mar 5;1(8323):498-501 [6131211.001]
  • [Cites] J Clin Invest. 1988 Jul;82(1):331-9 [2839550.001]
  • [Cites] Acta Neuropathol. 1993;86(4):360-4 [8256586.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4313-20 [8044778.001]
  • [Cites] J Neurooncol. 1995;24(1):33-6 [8523072.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):325-32 [8903474.001]
  • [Cites] Cell. 1997 Dec 26;91(7):869-72 [9428509.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4247-50 [15557427.001]
  • [Cites] Curr Opin Oncol. 2005 Mar;17(2):167-71 [15725923.001]
  • [Cites] Laryngoscope. 2005 Jul;115(7):1239-42 [15995513.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):640-8 [16056259.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9 [16174746.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:311-6 [17124077.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Dec;17(6):463-74 [17113338.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7469-81 [17143291.001]
  • [Cites] Expert Opin Ther Targets. 2007 Feb;11(2):219-34 [17227236.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Feb;292(2):C919-26 [17005603.001]
  • [Cites] World J Surg Oncol. 2007;5:17 [17286869.001]
  • [Cites] Neurobiol Aging. 2008 Dec;29(12):1874-93 [17560690.001]
  • [CommentIn] Blood. 2009 Jan 1;113(1):266-7; author reply 267-8 [19122120.001]
  • (PMID = 18184868.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108961; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / P30 CA15083; United States / NCI NIH HHS / CA / P50 CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2265457
  •  go-up   go-down


43. Rodriguez-Acebes S, Proctor I, Loddo M, Wollenschlaeger A, Rashid M, Falzon M, Prevost AT, Sainsbury R, Stoeber K, Williams GH: Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. Am J Pathol; 2010 Oct;177(4):2034-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment options for triple-receptor negative (ER-/PR-/Her2-) and Her2-overexpressing (ER-/PR-/Her2+) breast cancers with acquired or de novo resistance are limited, and metastatic disease remains incurable.
  • Targeting of growth signaling networks is often constrained by pathway redundancy or growth-independent cancer cell cycles.
  • Targeting Cdc7 with RNAi, we demonstrate that p53-mutant Her2-overexpressing and triple-negative breast cancer cell lines undergo an abortive S phase and apoptotic cell death due to loss of a p53-dependent Cdc7-inhibition checkpoint.
  • Emerging Cdc7 kinase inhibitors may therefore significantly broaden the therapeutic armamentarium for treatment of the aggressive p53-mutant breast cancer subtypes identified in this study.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):229-38 [11373098.001]
  • [Cites] Ann Oncol. 2010 Jun;21(6):1323-60 [19948741.001]
  • [Cites] Mol Cell Biol. 2002 Feb;22(3):874-85 [11784863.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2492-9 [12829668.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):262-9 [15199392.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7110-6 [15466207.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):892-7 [8492317.001]
  • [Cites] Mol Biol Cell. 1997 Feb;8(2):287-301 [9190208.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1474-81 [10334533.001]
  • [Cites] Anal Cell Pathol. 1998;17(4):189-200 [10391371.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] J Cell Sci. 2004 Nov 15;117(Pt 24):5875-86 [15522891.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2510-7 [15814627.001]
  • [Cites] IUBMB Life. 2005 Apr-May;57(4-5):323-35 [16036617.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5314-22 [15955899.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):56-67 [16005865.001]
  • [Cites] Ann Intern Med. 2005 Sep 20;143(6):446-57 [16172443.001]
  • [Cites] Adv Anat Pathol. 2005 Sep;12(5):256-64 [16210921.001]
  • [Cites] Cell. 2005 Oct 7;123(1):13-24 [16213209.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1734-6 [16236745.001]
  • [Cites] Br J Cancer. 2005 Nov 28;93(11):1295-300 [16278669.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10281-90 [16446360.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Int J Gynecol Cancer. 2006;16 Suppl 2:543-8 [17010069.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R34 [16846532.001]
  • [Cites] Mol Cell Biol. 2007 Aug;27(16):5806-18 [17515603.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6153-61 [17947481.001]
  • [Cites] Curr Opin Cell Biol. 2007 Dec;19(6):672-9 [18032010.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):137-42 [18043578.001]
  • [Cites] Oncologist. 2008 Apr;13(4):373-81 [18448551.001]
  • [Cites] Cancer. 2008 May 15;112(10):2130-42 [18383519.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(1):27-44 [17922188.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):799-806 [18756287.001]
  • [Cites] Eur J Cancer. 2008 Dec;44(18):2781-90 [19013786.001]
  • [Cites] Br J Cancer. 2009 Mar 24;100(6):959-70 [19240714.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2417-25 [19318489.001]
  • [Cites] Breast Cancer Res. 2009;11(4):208 [19744307.001]
  • [Cites] Breast Cancer Res Treat. 2009 Dec;118(3):481-98 [19169812.001]
  • [Cites] Curr Opin Cell Biol. 2009 Dec;21(6):771-7 [19767190.001]
  • [Cites] Eur J Cancer. 2010 Jan;46(1):33-40 [19815406.001]
  • [Cites] Genome Biol. 2008;9(10):R149 [18847512.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • (PMID = 20724597.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / C428/A6263
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.1.- / CDC7 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2947297
  •  go-up   go-down


44. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z: A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis; 2009 Jun;24(6):677-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer.
  • PURPOSE: Bevacizumab has demonstrated survival benefit in metastatic colorectal cancer (mCRC) patients when combined with chemotherapy.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Aug 22;352(9128):609-13 [9746022.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):792-9 [15681523.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Nan Fang Yi Ke Da Xue Xue Bao. 2006 May;26(5):689-91 [16762887.001]
  • [Cites] Eur J Cancer. 1996;32A Suppl 3:S18-23 [8943661.001]
  • [Cites] J Clin Oncol. 2008 Apr 20;26(12):2013-9 [18421054.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23 ):2335-42 [15175435.001]
  • [Cites] Stat Med. 1998 Dec 30;17(24):2815-34 [9921604.001]
  • [Cites] Microsc Res Tech. 2003 Feb 1;60(2):199-207 [12539174.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):808-15 [9053508.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1407-12 [9807986.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3502-8 [15908660.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1413-8 [9807987.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23 (16):3697-705 [15738537.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] Lancet Oncol. 2006 Sep;7(9):741-6 [16945769.001]
  • [Cites] J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9 [17686822.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2205-11 [17470850.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):431-7 [10945486.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1539-44 [17442997.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Oncology. 2005;69 Suppl 3:25-33 [16301833.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):251-60 [8996150.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343 (13):905-14 [11006366.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001545 [10796809.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):60-5 [12506171.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Control Clin Trials. 1996 Feb;17(1):1-12 [8721797.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:3-10 [10804084.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Mol Med (Berl). 1999 Jul;77(7):527-43 [10494799.001]
  • [Cites] Ann Intern Med. 2001 Dec 4;135(11):982-9 [11730399.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):77-82 [15221991.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):2938-47 [10944126.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12 ):5365-73 [15958585.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):214-9 [9135491.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):896-903 [1534121.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):786-95 [10091755.001]
  • [Cites] Semin Oncol. 1996 Feb;23 (1 Suppl 3):34-41 [8633252.001]
  • (PMID = 19184059.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


45. Barthel SR, Gavino JD, Wiese GK, Jaynes JM, Siddiqui J, Dimitroff CJ: Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. Glycobiology; 2008 Oct;18(10):806-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin.
  • Prostate cancer (PCa) cell tethering and rolling on microvascular endothelium has been proposed to promote the extravasation of PCa cells.
  • Prior data indicate that E-selectin-mediated rolling of bone-metastatic PCa MDA PCa 2b (MDA) cells is dependent on sialyl Lewis X (sLe(X))-bearing glycoproteins.
  • To explore the molecular basis of sLe(X) synthesis and E-selectin ligand (ESL) activity on PCa cells, we compared and contrasted the expression level of glycosyltransferases, characteristically involved in sLe(X) and ESL synthesis, in ESL(+) MDA cells among other ESL(-) metastatic PCa cell lines.
  • We found that normal prostate tissue and all metastatic PCa cell lines expressed glycosyltransferases required for sialo-lactosamine synthesis, including N-acetylglucosaminyl-, galactosyl-, and sialyltransferases.
  • These results implicate the importance of alpha1,3 FT3, FT6, and/or FT7 in sLe(X) and ESL synthesis on metastatic PCa cells.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2493-500 [9815652.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2127-35 [10232599.001]
  • [Cites] Glycoconj J. 1998 Dec;15(12):1155-63 [10372971.001]
  • [Cites] Br J Cancer. 1999 Jun;80(8):1169-74 [10376968.001]
  • [Cites] Biochim Biophys Acta. 1999 Aug 5;1428(2-3):209-18 [10434038.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):70-9 [10449611.001]
  • [Cites] Clin Exp Immunol. 1999 Sep;117(3):430-4 [10469043.001]
  • [Cites] Lab Invest. 2004 Dec;84(12):1666-76 [15467730.001]
  • [Cites] Glycobiology. 2005 Mar;15(3):271-80 [15483269.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2A):875-9 [15868922.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 22;333(1):131-7 [15939404.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5750-60 [15994950.001]
  • [Cites] Biochim Biophys Acta. 2005 Oct 15;1731(1):66-73 [16199102.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):290-301 [16756721.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4742-8 [16982914.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31353-60 [10882744.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):558-65 [11058871.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4839-47 [11156243.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5702-11 [15313910.001]
  • [Cites] Science. 1990 Nov 23;250(4984):1130-2 [1701274.001]
  • [Cites] Gastroenterology. 1992 Feb;102(2):424-30 [1732113.001]
  • [Cites] Int J Cancer. 1993 Jul 30;54(6):972-7 [7687590.001]
  • [Cites] Cancer Res. 1995 May 1;55(9):1817-9 [7728744.001]
  • [Cites] Genomics. 1995 Mar 1;26(1):142-6 [7782074.001]
  • [Cites] Hum Pathol. 1995 Jul;26(7):735-9 [7628844.001]
  • [Cites] J Biol Chem. 1995 Aug 25;270(34):20112-22 [7650030.001]
  • [Cites] J Cell Biochem. 1995 Jul;58(3):292-304 [7593252.001]
  • [Cites] Int J Cancer. 1995 Nov 15;63(4):551-9 [7591266.001]
  • [Cites] Cancer Metastasis Rev. 1995 Sep;14(3):219-28 [8548870.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):325-9 [8542587.001]
  • [Cites] J Biol Chem. 1996 Apr 26;271(17):10317-28 [8626601.001]
  • [Cites] J Cell Biol. 1996 May;133(4):911-20 [8666674.001]
  • [Cites] Anal Biochem. 1996 Jul 1;238(2):184-90 [8660609.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2125-32 [8822932.001]
  • [Cites] Glycoconj J. 1997 Jan;14(1):147-53 [9076523.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16100-6 [11278338.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1417-23 [11355957.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):17949-57 [11278609.001]
  • [Cites] J Cell Biol. 2001 Jun 11;153(6):1277-86 [11402070.001]
  • [Cites] Immunity. 2001 Jul;15(1):115-26 [11485743.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):601-14 [11535629.001]
  • [Cites] Glycobiology. 2001 Oct;11(10):119R-128R [11588153.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] Clin Exp Metastasis. 2002;19(1):25-33 [11918080.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4063-9 [12010808.001]
  • [Cites] Am Fam Physician. 2002 May 1;65(9):1834-40 [12018806.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):321-31 [12085969.001]
  • [Cites] J Clin Invest. 2002 Aug;110(4):559-69 [12189250.001]
  • [Cites] Immunol Rev. 2002 Aug;186:19-36 [12234359.001]
  • [Cites] Trends Immunol. 2003 Mar;24(3):101-4 [12615200.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Mar;84(4):411-22 [12732286.001]
  • [Cites] J Cell Biochem. 2003 Jun 1;89(3):462-73 [12761880.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3805-11 [12839977.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2060-7 [12763924.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):531-8 [14519387.001]
  • [Cites] Clin Exp Metastasis. 2003;20(5):413-20 [14524530.001]
  • [Cites] Annu Rev Biochem. 2003;72:643-91 [12676797.001]
  • [Cites] Adv Exp Med Biol. 2001;491:267-78 [14533803.001]
  • [Cites] Adv Exp Med Biol. 2001;491:587-630 [14533823.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Sep;22(3):431-40 [14582703.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):949-57 [14601054.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2004 May 7;42(9):546-50 [15196369.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5261-9 [15289332.001]
  • [Cites] Cancer Lett. 2006 Oct 28;242(2):191-7 [16427187.001]
  • [Cites] Biol Pharm Bull. 2006 Dec;29(12):2372-7 [17142966.001]
  • [Cites] Expert Opin Ther Targets. 2007 Nov;11(11):1473-91 [18028011.001]
  • [Cites] J Allergy Clin Immunol. 2008 Jan;121(1):148-157.e3 [17910894.001]
  • [Cites] J Biochem. 2008 Jun;143(6):725-9 [18218651.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1092-9 [18281484.001]
  • [Cites] Blood. 1999 Dec 15;94(12):4011-9 [10590044.001]
  • [Cites] Mol Carcinog. 2000 Apr;27(4):280-8 [10747292.001]
  • [Cites] Immunity. 2000 Jun;12(6):665-76 [10894166.001]
  • [Cites] Leuk Lymphoma. 2000 Sep;39(1-2):185-94 [10975398.001]
  • [Cites] Glycobiology. 1997 Apr;7(3):357-65 [9147044.001]
  • [Cites] Glycobiology. 1997 Sep;7(6):835-46 [9376686.001]
  • [Cites] J Biol Chem. 1997 Nov 21;272(47):29721-8 [9368041.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):118-23 [9450571.001]
  • [Cites] Glycoconj J. 1997 Nov;14(7):875-7 [9511995.001]
  • [Cites] Int J Oncol. 1998 May;12(5):1157-64 [9538143.001]
  • [Cites] Glycobiology. 1998 Jun;8(6):605-13 [9592127.001]
  • [Cites] J Immunol. 1998 Dec 1;161(11):6305-15 [9834120.001]
  • (PMID = 18647941.001).
  • [ISSN] 1460-2423
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118124; United States / NIAMS NIH HHS / AR / P30 AR042689; United States / NCI NIH HHS / CA / R01CA118124
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / E-Selectin; 0 / Ligands; 0 / Oligosaccharides; EC 2.4.- / Glycosyltransferases
  • [Other-IDs] NLM/ NIHMS62214; NLM/ PMC2574550
  •  go-up   go-down


46. Ibrahim A, Crockard A, Antonietti P, Boriani S, Bünger C, Gasbarrini A, Grejs A, Harms J, Kawahara N, Mazel C, Melcher R, Tomita K: Does spinal surgery improve the quality of life for those with extradural (spinal) osseous metastases? An international multicenter prospective observational study of 223 patients. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2007. J Neurosurg Spine; 2008 Mar;8(3):271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study the authors set out to ascertain if surgery improves the quality of remaining life in patients with spinal metastatic and tumor-related systemic disease.
  • Although not a treatment of the systemic cancer, surgery is feasible, has acceptably low mortality and morbidity rates, and for many will improve the quality of their remaining life.
  • [MeSH-major] Bone Neoplasms / secondary. Bone Neoplasms / surgery. International Cooperation. Neoplasms, Second Primary / surgery. Quality of Life / psychology. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery
  • [MeSH-minor] Anal Canal / physiopathology. Female. Humans. Incidence. Laminectomy. Male. Middle Aged. Observation. Postoperative Care / mortality. Prospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312079.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Iagaru A, Kundu R, Jadvar H, Nagle D: Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma. Hell J Nucl Med; 2009 Jan-Apr;12(1):26-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation by 18F-FDG-PET of patients with anal squamous cell carcinoma.
  • Anal squamous cell carcinoma (ASCC) is a rare cancer of the gastrointestinal tract, representing less than 5% of the digestive malignancies.
  • Our results showed that PET demonstrated the primary lesion at initial evaluation in 7 of 8 anal cancers and showed FDG- avid lymph nodes in 4 patients.
  • Metastatic nodal involvement was confirmed by pathology in 2 patients; in the other 2 patients pathology showed reactive follicular hyperplasia.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19330178.001).
  • [ISSN] 1790-5427
  • [Journal-full-title] Hellenic journal of nuclear medicine
  • [ISO-abbreviation] Hell J Nucl Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


48. Al-Sukhni W, McLeod RS, MacRae H, O'Connor B, Huang H, Cohen Z: Oncologic outcome in patients with ulcerative colitis associated with dyplasia or cancer who underwent stapled or handsewn ileal pouch-anal anastomosis. Dis Colon Rectum; 2010 Nov;53(11):1495-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncologic outcome in patients with ulcerative colitis associated with dyplasia or cancer who underwent stapled or handsewn ileal pouch-anal anastomosis.
  • PURPOSE: Ulcerative colitis is a risk factor for colorectal cancer.
  • Restorative proctocolectomy with ileal pouch-anal anastomosis is a standard surgical management of patients with ulcerative colitis who have cancer or dysplasia, but the oncologic risk of stapled anastomosis vs mucosectomy with handsewn anastomosis is debated.
  • We compare the risk of new cancer or recurrence in the pouch or rectal cuff in patients with ulcerative colitis undergoing stapled anastomosis vs mucosectomy with handsewn anastomosis.
  • The patients with ulcerative colitis associated with colorectal dysplasia or cancer who underwent ileal pouch-anal anastomosis between 1981 and 2009 were evaluated.
  • The development of dysplasia or cancer at ileoanal anastomosis or in the pelvic pouch was assessed.
  • RESULTS: Eighty-one patients underwent stapled (n = 59) or handsewn (n = 22) ileal pouch-anal anastomosis; 52 had evidence of dysplasia and 29 had colorectal cancer (24 colon; 5 rectum) at the time of surgery.
  • Two of 10 (20%) patients with handsewn anastomosis and 0% patients with stapled anastomosis developed metastatic cancer.
  • One patient with a 33-year history of colitis, a previously resected right-sided colon cancer, and subsequent high-grade dysplasia in the rectum underwent a handsewn pelvic pouch and developed an unresectable adenocarcinoma at the cuff 4 years later.
  • Of those patients, both colorectal cancer-related deaths were in patients with handsewn anastomoses.
  • CONCLUSIONS: Performing a stapled ileal pelvic anal anastomosis does not appear to be inferior to mucosectomy and handsewn anastomosis in oncologic outcome, and it seems appropriate in patients with ulcerative colitis associated with coexisting dysplasia or cancer.


49. Yam C, Zhao M, Hayashi K, Ma H, Kishimoto H, McElroy M, Bouvet M, Hoffman RM: Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res; 2010 Dec;164(2):248-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer.
  • Cancer of the exocrine pancreas is the fourth leading cause of cancer deaths in the United States.
  • The majority of patients present with locally-advanced or metastatic disease.
  • We report here a modified auxotrophic strain of S. typhimurium that can target and inhibit the growth of liver metastasis in a mouse model of pancreatic cancer.
  • In the present study, we demonstrate the efficacy of locally- as well as systemically-administered A1-R on liver metastasis of pancreatic cancer.
  • This study suggests the clinical potential of bacterial treatment of a critical metastatic target of pancreatic cancer.

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer Res. 1964 Feb;24:222-33 [14115688.001]
  • [Cites] Cancer Res. 1964 Feb;24:217-21 [14115687.001]
  • [Cites] JOP. 2006;7(2):193-9 [16525203.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4208-14 [16618743.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7647-52 [16885365.001]
  • [Cites] Cancer Biol Ther. 2006 Sep;5(9):1120-8 [16855381.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11293-7 [17145875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10170-4 [17548809.001]
  • [Cites] Cancer Gene Ther. 2000 Feb;7(2):269-74 [10770636.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1027-30 [10772643.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1996-2002 [10837181.001]
  • [Cites] Breast Cancer Res Treat. 2001 Mar;66(2):165-70 [11437103.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15155-60 [11724950.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):142-52 [11773163.001]
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(6):964-72 [12879198.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):313-20 [14990953.001]
  • [Cites] Gan. 1978 Oct;69(5):613-8 [729960.001]
  • [Cites] Cancer Res. 1980 Jun;40(6):2061-8 [6989495.001]
  • [Cites] Nature. 1981 May 21;291(5812):238-9 [7015147.001]
  • [Cites] Gene Ther. 1996 Feb;3(2):173-8 [8867865.001]
  • [Cites] Gene Ther. 1997 Aug;4(8):791-6 [9338007.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4537-44 [9377566.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1408-16 [9537241.001]
  • [Cites] Nat Biotechnol. 1999 Jan;17(1):37-41 [9920266.001]
  • [Cites] Cancer Res. 1955 Aug;15(7):473-8 [13240693.001]
  • [Cites] Cancer Res. 1964 Feb;24:212-6 [14115686.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):755-60 [15644448.001]
  • (PMID = 19766244.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA121938; United States / NCI NIH HHS / CA / R01 CA132971-01A1; United States / NCI NIH HHS / CA / R33 CA109949-03; United States / NCI NIH HHS / CA / R33 CA109949; United States / NCI NIH HHS / CA / CA119841; United States / NCI NIH HHS / CA / CA126023; United States / NCI NIH HHS / CA / R01 CA132971; United States / NCI NIH HHS / CA / R33 CA109949-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrosoguanidines
  • [Other-IDs] NLM/ NIHMS100322; NLM/ PMC2888721
  •  go-up   go-down


50. Gaertner WB, Hagerman GF, Finne CO, Alavi K, Jessurun J, Rothenberger DA, Madoff RD: Fistula-associated anal adenocarcinoma: good results with aggressive therapy. Dis Colon Rectum; 2008 Jul;51(7):1061-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma: good results with aggressive therapy.
  • PURPOSE: To evaluate the clinical features, pathology, treatment, and outcome of patients with fistula-associated anal adenocarcinoma.
  • METHODS: We identified 14 patients with histologically proven fistula-associated anal adenocarcinoma.
  • Eleven patients had preexisting chronic anal fistulas.
  • The diagnosis of cancer was suspected during physical examination in 6 of the 14 patients (43 percent).
  • Four patients died with metastatic disease.
  • CONCLUSIONS: The diagnosis of fistula-associated anal adenocarcinoma is often unsuspected.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418652.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Wondrak GT: NQO1-activated phenothiazinium redox cyclers for the targeted bioreductive induction of cancer cell apoptosis. Free Radic Biol Med; 2007 Jul 15;43(2):178-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NQO1-activated phenothiazinium redox cyclers for the targeted bioreductive induction of cancer cell apoptosis.
  • Altered redox signaling and regulation in cancer cells represent a chemical vulnerability that can be targeted by selective chemotherapeutic intervention.
  • Here, we demonstrate that 3,7-diaminophenothiazinium-based redox cyclers (PRC) induce selective cancer cell apoptosis by NAD(P)H:quinone oxidoreductase (NQO1)-dependent bioreductive generation of cellular oxidative stress.
  • Using PRC lead compounds including toluidine blue against human metastatic G361 melanoma cells, apoptosis occurred with phosphatidylserine externalization, loss of mitochondrial transmembrane potential, cytochrome c release, caspase-3 activation, and massive ROS production.
  • The critical role of NQO1 in PRC bioactivation and cytotoxicity was confirmed, when NQO1-transfected breast cancer cells (MCF7-DT15) stably overexpressing active NQO1 displayed strongly enhanced PRC sensitivity as compared to vector control-transfected cells with baseline NQO1 activity.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PHENOTHIAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Heart Circ Physiol. 2000 Jan;278(1):H137-50 [10644593.001]
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2063-73 [10545407.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3638-44 [10910079.001]
  • [Cites] Free Radic Biol Med. 2000 May 1;28(9):1338-48 [10924853.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Mar;280(3):C659-76 [11171586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5550-5 [11331784.001]
  • [Cites] Free Radic Biol Med. 2001 Jun 1;30(11):1191-212 [11368918.001]
  • [Cites] Pigment Cell Res. 2001 Jun;14(3):148-54 [11434561.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3215-21 [11595717.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jun;282(6):C1212-24 [11997235.001]
  • [Cites] Methods Enzymol. 2002;352:91-100 [12125380.001]
  • [Cites] Biochem Pharmacol. 2002 Dec 1;64(11):1597-603 [12429349.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8786-803 [12483532.001]
  • [Cites] Curr Drug Targets. 2003 Feb;4(2):133-41 [12558066.001]
  • [Cites] Photochem Photobiol Sci. 2002 Nov;1(11):852-6 [12659523.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5513-20 [14500388.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Mar;53(3):209-19 [14610616.001]
  • [Cites] Methods Enzymol. 2004;382:115-44 [15047100.001]
  • [Cites] Antioxid Redox Signal. 2004 Jun;6(3):561-70 [15130282.001]
  • [Cites] Cancer Treat Rev. 2004 Aug;30(5):437-49 [15245776.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30009-20 [15133022.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(13):1934-40 [15315800.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):771-6 [15386380.001]
  • [Cites] J Biol Chem. 1985 Dec 5;260(28):15168-71 [4066667.001]
  • [Cites] Clin Chem. 1986 Jan;32(1 Pt 1):177-9 [3940703.001]
  • [Cites] Eur J Biochem. 1991 Jan 1;195(1):171-6 [1899380.001]
  • [Cites] Anal Biochem. 1992 Mar;201(2):375-80 [1632527.001]
  • [Cites] Biochem Pharmacol. 1996 Mar 8;51(5):693-700 [8615907.001]
  • [Cites] Acta Oncol. 1996;35(3):331-41 [8679265.001]
  • [Cites] FEBS Lett. 1997 Jul 21;412(1):157-60 [9257711.001]
  • [Cites] J Photochem Photobiol B. 1997 Oct;40(3):233-9 [9372612.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):9357-60 [9545256.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):769-73 [9845093.001]
  • [Cites] Biochem Soc Trans. 1998 Nov;26(4):S319 [10047833.001]
  • [Cites] Br J Cancer. 1999 Jun;80(8):1223-30 [10376975.001]
  • [Cites] Free Radic Biol Med. 1999 Jul;27(1-2):146-59 [10443931.001]
  • [Cites] Nature. 1999 Sep 2;401(6748):79-82 [10485709.001]
  • [Cites] Biochim Biophys Acta. 1962 Apr 9;58:171-88 [13890666.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6914-20 [15615540.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Feb;312(2):482-91 [15475591.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):948-56 [15705895.001]
  • [Cites] Am J Surg. 2005 Feb;189(2):236-9 [15720998.001]
  • [Cites] Trop Med Int Health. 2005 Jun;10(6):501-11 [15941412.001]
  • [Cites] Org Biomol Chem. 2005 Jul 21;3(14):2579-87 [15999190.001]
  • [Cites] Mol Carcinog. 2005 Aug;43(4):215-24 [16003741.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8017-21 [16140975.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Dec;56(6):659-65 [16052340.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Feb;316(2):805-14 [16210394.001]
  • [Cites] Cancer Lett. 2006 Feb 8;232(2):214-25 [16458118.001]
  • [Cites] Curr Pharm Des. 2006;12(34):4427-43 [17168752.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):695-705 [17160708.001]
  • [Cites] Ann Emerg Med. 1999 Nov;34(5):646-56 [10533013.001]
  • [Cites] Front Biosci. 2000 Jul 1;5:D639-48 [10877993.001]
  • (PMID = 17603928.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA95060; United States / NIEHS NIH HHS / ES / ES06694; United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NCI NIH HHS / CA / CA095060-04; United States / NIEHS NIH HHS / ES / ES006694-11A19006; United States / NCI NIH HHS / CA / P50 CA095060; United States / NCI NIH HHS / CA / P50 CA095060-04; United States / NIEHS NIH HHS / ES / P30 ES006694-11A19006
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phenothiazines; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 3.4.22.- / Caspase 3; GS9EX7QNU6 / phenothiazine
  • [Other-IDs] NLM/ NIHMS27138; NLM/ PMC2705808
  •  go-up   go-down


52. Morello E, Martano M, Squassino C, Iussich S, Caccamo R, Sammartano F, Zabarino S, Bellino C, Pisani G, Buracco P: Transanal pull-through rectal amputation for treatment of colorectal carcinoma in 11 dogs. Vet Surg; 2008 Jul;37(5):420-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal pull-through rectal amputation for treatment of colorectal carcinoma in 11 dogs.
  • OBJECTIVE: To evaluate outcome after transanal rectal pull-through amputation of single colorectal adenocarcinoma and in situ carcinoma (Tis) in dogs.
  • ANIMALS: Dogs (n=11) with colorectal cancer.
  • Postoperative recurrence and metastatic rates for adenocarcinoma were 18.2% and 0%, respectively.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Canal / surgery. Colorectal Neoplasms / veterinary. Dog Diseases / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18986308.001).
  • [ISSN] 1532-950X
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Pocard M, Sabourin JC: [Not Available]. J Chir (Paris); 2008 Dec;145(6S1):12S17-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sabourin In theory, the concept of sentinel lymph node (SLN) biopsy can be applied to cancer surgery for all solid cancers.
  • Yet sentinel lymph node biopsy has not become a standard part of gastrointestinal cancer surgery.
  • Studies of SLN biopsy in colon cancer have not shown it to be a reliable predictor of N+ status and therefore don't permit the omission of lymph node dissection in selected cases.
  • SLN biopsy may have prognostic usefulness by demonstrating micrometastases; careful serial sectioning focussed on the SLN may detect nests of metastatic cells on HE staining, thereby converting a tumor from Stage I (TxN0M0) to Stage II (TxN1M0).
  • For cancers of the anal canal, SLN biopsy of inguinal nodes has been tested as a means of establishing the indications for inguinal lymph node dissection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier Masson SAS. All rights reserved.
  • (PMID = 22794067.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


54. Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB: A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist; 2010;15(7):699-731
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.
  • Rapidly growing insights into the molecular biology of colorectal cancer (CRC) and recent developments in gene sequencing and molecular diagnostics have led to high expectations for the identification of molecular markers to be used in optimized and tailored treatment regimens.
  • However, many of the published data on molecular biomarkers are contradictory in their findings and the current reality is that no molecular marker, other than the KRAS gene in the case of epidermal growth factor receptor (EGFR)- targeted therapy for metastatic disease, has made it into clinical practice.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fam Cancer. 2009;8(3):231-9 [19165625.001]
  • [Cites] Br J Cancer. 2009 Aug 4;101(3):465-72 [19603024.001]
  • [Cites] Cancer. 2009 Aug 15;115(16):3609-17 [19526592.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):715-21 [19603018.001]
  • [Cites] Gut. 2009 Sep;58(9):1234-41 [19474002.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):528-34 [19597509.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Sep;6(9):519-27 [19636327.001]
  • [Cites] Mod Pathol. 2009 Sep;22(9):1186-95 [19503063.001]
  • [Cites] Oncology. 2009;77(3-4):224-30 [19738388.001]
  • [Cites] Arch Surg. 2009 Sep;144(9):835-40 [19797108.001]
  • [Cites] J Clin Oncol. 2009 Sep 20;27(27):4591-8 [19704056.001]
  • [Cites] Br J Surg. 2009 Oct;96(10):1196-204 [19787768.001]
  • [Cites] PLoS One. 2009;4(10):e7287 [19806185.001]
  • [Cites] J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24 [19738166.001]
  • [Cites] Br J Cancer. 2009 Oct 20;101(8):1382-92 [19755986.001]
  • [Cites] Clin Cancer Res. 2009 Oct 15;15(20):6412-20 [19825961.001]
  • [Cites] J Pathol. 2009 Nov;219(3):337-46 [19697359.001]
  • [Cites] Curr Drug Targets. 2009 Oct;10(10):1033-40 [19663767.001]
  • [Cites] Am J Clin Oncol. 2009 Jun;32(3):245-52 [19451802.001]
  • [Cites] J Pathol. 2009 Dec;219(4):435-45 [19824059.001]
  • [Cites] Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1310-5 [19950782.001]
  • [Cites] Clin Cancer Res. 2009 Dec 1;15(23):7322-9 [19934290.001]
  • [Cites] Am J Ther. 2009 Nov-Dec;16(6):554-61 [19352138.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5931-7 [19884549.001]
  • [Cites] J Clin Oncol. 2009 Dec 10;27(35):5924-30 [19884556.001]
  • [Cites] Br J Cancer. 2010 Jan 5;102(1):151-61 [19935791.001]
  • [Cites] J Clin Oncol. 2010 Jan 20;28(3):466-74 [20008640.001]
  • [Cites] Target Oncol. 2009 Dec;4(4):311-22 [19915942.001]
  • [Cites] Virchows Arch. 2009 Dec;455(6):485-94 [19911194.001]
  • [Cites] Histopathology. 2010 Jan;56(2):229-39 [20102402.001]
  • [Cites] Ann Surg Oncol. 2010 Feb;17(2):572-8 [19727962.001]
  • [Cites] Ann Surg Oncol. 2010 Feb;17(2):416-24 [19813061.001]
  • [Cites] Cancer Immunol Immunother. 2010 May;59(5):653-61 [19908042.001]
  • [Cites] Ann Surg Oncol. 2010 Apr;17(4):1168-76 [19936839.001]
  • [Cites] Int J Cancer. 2010 Jun 1;126(11):2635-43 [19856313.001]
  • [Cites] Int J Cancer. 2010 Jul 15;127(2):367-80 [19908233.001]
  • [Cites] J Mol Diagn. 2008 Jan;10(1):13-27 [18165277.001]
  • [Cites] Pathol Int. 2008 Feb;58(2):104-13 [18199160.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):374-9 [18202412.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):380-5 [18202413.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):243-50 [17961631.001]
  • [Cites] Cancer. 2008 Feb 1;112(3):495-502 [18076013.001]
  • [Cites] Ann Oncol. 2008 Mar;19(3):508-15 [17998284.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Apr;66(1):21-30 [18206383.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1427-34 [18349392.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2255-9 [18224685.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):717-23 [17974556.001]
  • [Cites] Ann Oncol. 2008 Apr;19(4):734-8 [18272912.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jun;57(6):813-21 [17962941.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):561-72 [18402523.001]
  • [Cites] Mol Diagn Ther. 2008;12(2):87-98 [18422373.001]
  • [Cites] J Clin Pathol. 2008 May;61(5):561-9 [18326017.001]
  • [Cites] Gut. 2008 Jun;57(6):772-9 [17965063.001]
  • [Cites] Am J Surg. 2008 Jun;195(6):719-25 [18440486.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3798-806 [18559599.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):83-9 [18577988.001]
  • [Cites] Clin Colorectal Cancer. 2008 May;7(3):184-90 [18621636.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4830-5 [18676755.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5869-76 [18794099.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):413-8 [18619559.001]
  • [Cites] Int J Colorectal Dis. 2008 Nov;23(11):1033-9 [18594845.001]
  • [Cites] Cancer Res. 2008 Oct 15;68(20):8541-6 [18922929.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] Clin Chem. 2008 Nov;54(11):1770-9 [18801934.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2288-95 [18707864.001]
  • [Cites] Eur J Surg Oncol. 2008 Dec;34(12):1316-21 [18313881.001]
  • [Cites] Br J Cancer. 2008 Dec 2;99(11):1867-73 [18985040.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7884-95 [19047118.001]
  • [Cites] Clin Colorectal Cancer. 2008 Dec;7 Suppl 2:S52-7 [19064407.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5705-12 [19001320.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Aug 1;28(3):269-81 [19086328.001]
  • [Cites] Gut. 2009 Jan;58(1):90-6 [18832519.001]
  • [Cites] BMC Gastroenterol. 2008;8:56 [19036165.001]
  • [Cites] J Clin Oncol. 2009 Jan 10;27(2):186-92 [19064967.001]
  • [Cites] Ann Oncol. 2009 Jan;20(1):84-90 [18669866.001]
  • [Cites] Oncologist. 2009 Jan;14(1):29-39 [19144681.001]
  • [Cites] N Engl J Med. 2009 Feb 5;360(6):563-72 [19196673.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):663-71 [19114683.001]
  • [Cites] J Clin Oncol. 2009 Mar 1;27(7):1130-6 [19124802.001]
  • [Cites] Cancer Res. 2009 Mar 1;69(5):1851-7 [19223544.001]
  • [Cites] Clin Adv Hematol Oncol. 2009 Jan;7(1):45-53, 64 [19274041.001]
  • [Cites] J Hematol Oncol. 2009;2:9 [19236713.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1477-84 [19237633.001]
  • [Cites] Br J Cancer. 2009 Apr 7;100(7):1087-94 [19293803.001]
  • [Cites] N Engl J Med. 2009 Apr 2;360(14):1408-17 [19339720.001]
  • [Cites] Target Oncol. 2009 Jan;4(1):57-62 [19343302.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):262-71 [19117687.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2091-6 [19188670.001]
  • [Cites] Ann Oncol. 2009 May;20(5):879-84 [19179548.001]
  • [Cites] Clin Cancer Res. 2009 May 1;15(9):3184-8 [19366826.001]
  • [Cites] J Hematol Oncol. 2009;2:18 [19386128.001]
  • [Cites] J Clin Oncol. 2009 Jun 1;27(16):2622-9 [19398573.001]
  • [Cites] Cancer Biother Radiopharm. 2009 Jun;24(3):369-76 [19538060.001]
  • [Cites] Mol Diagn Ther. 2009;13(2):103-14 [19537845.001]
  • [Cites] Adv Anat Pathol. 2009 Jul;16(4):196-203 [19546608.001]
  • [Cites] Colorectal Dis. 2009 Jul;11(6):601-8 [18637931.001]
  • [Cites] Clin Transl Oncol. 2009 Jul;11(7):465-9 [19574205.001]
  • [Cites] Clin Colorectal Cancer. 2009 Jul;8(3):135-40 [19632927.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] Isr Med Assoc J. 2005 Aug;7(8):520-4 [16106779.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5635-43 [16110022.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):837-45 [16143123.001]
  • [Cites] Semin Cancer Biol. 2005 Dec;15(6):484-93 [16055342.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2060-70 [16125380.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8332-40 [16322293.001]
  • [Cites] Histopathology. 2005 Dec;47(6):560-4 [16324192.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):145-54 [16126346.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):127-44 [16139957.001]
  • [Cites] Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80 [16336752.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Int J Oncol. 2006 Feb;28(2):329-35 [16391786.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1721-7 [16231316.001]
  • [Cites] Mol Cell Biol. 2006 Feb;26(4):1170-82 [16449633.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1144-51 [16489067.001]
  • [Cites] Expert Opin Ther Targets. 2006 Apr;10(2):281-7 [16548776.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):395-406 [16555243.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3992-5 [16618717.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Apr;28(2):61-8 [16637508.001]
  • [Cites] Am J Surg. 2006 May;191(5):646-51 [16647353.001]
  • [Cites] Invest New Drugs. 2006 Mar;24(2):99-110 [16502353.001]
  • [Cites] Cancer J. 2006 May-Jun;12(3):229-36 [16803682.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1728-43 [16815701.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1302-9 [16763611.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Oct 15;24(8):1163-77 [17014575.001]
  • [Cites] Oncologist. 2006 Oct;11(9):973-80 [17030637.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4914-21 [17050875.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):986-92; discussion 992-3 [17122624.001]
  • [Cites] Adv Exp Med Biol. 2006;587:161-77 [17163165.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):145-52 [16724208.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):158-63 [16953233.001]
  • [Cites] PLoS One. 2006;1:e129 [17205133.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):624-31 [17223543.001]
  • [Cites] Cancer Immun. 2007;7:4 [17311363.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):793-800 [17311026.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1229-36 [17195912.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1B):627-33 [17348452.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2643-8 [17363584.001]
  • [Cites] Cancer Immun. 2007;7:7 [17388261.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1166-9 [17375050.001]
  • [Cites] Virchows Arch. 2007 May;450(5):529-37 [17372756.001]
  • [Cites] Int J Colorectal Dis. 2007 Jul;22(7):739-48 [17109103.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3831-9 [17606714.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):219-31 [17631144.001]
  • [Cites] Dis Colon Rectum. 2007 Aug;50(8):1259-70 [17566832.001]
  • [Cites] Pathol Res Pract. 2007;203(7):489-97 [17629419.001]
  • [Cites] World J Gastroenterol. 2007 Jul 28;13(28):3784-91 [17657831.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3230-7 [17664471.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3238-45 [17664472.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1771-8 [17590872.001]
  • [Cites] J Clin Pathol. 2007 Oct;60(10):1112-6 [17182662.001]
  • [Cites] Gut. 2007 Nov;56(11):1572-8 [17566017.001]
  • [Cites] Br J Cancer. 2007 Oct 22;97(8):1139-45 [17940504.001]
  • [Cites] Clin Cancer Res. 2007 Oct 15;13(20):6093-8 [17947473.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s [18006800.001]
  • [Cites] Clin Colorectal Cancer. 2007 Nov;6(10):683-90 [18039421.001]
  • [Cites] Oncology. 2007;72(1-2):82-8 [18004081.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(6):1071-87 [18070704.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jan;65(1):8-20 [18006328.001]
  • [Cites] Anticancer Drugs. 2008 Feb;19(2):99-113 [18176106.001]
  • [Cites] Br J Surg. 2004 Oct;91(10):1275-91 [15382104.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Int J Colorectal Dis. 2004 Nov;19(6):533-7 [15175889.001]
  • [Cites] J Clin Pathol. 1986 Jun;39(6):585-9 [3722412.001]
  • [Cites] JAMA. 1989 Jun 2;261(21):3099-103 [2654431.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;416(4):343-9 [2106751.001]
  • [Cites] Br J Surg. 1990 Dec;77(12):1352-4 [2276016.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1136-41 [1551522.001]
  • [Cites] Mod Pathol. 1992 Mar;5(2):131-4 [1574489.001]
  • [Cites] Int J Cancer. 1992 Aug 19;52(1):30-3 [1500224.001]
  • [Cites] Cancer. 1992 Sep 15;70(6 Suppl):1732-9 [1516028.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):57-64 [8419262.001]
  • [Cites] Oncology. 1993;50(1):70-6 [8421601.001]
  • [Cites] Gastroenterology. 1993 Apr;104(4):1044-8 [8462792.001]
  • [Cites] J Biol Chem. 1993 Apr 25;268(12):8617-23 [7682552.001]
  • [Cites] Arch Surg. 1993 May;128(5):526-31; discussion 531-2 [8489386.001]
  • [Cites] Surg Oncol. 1992 Feb;1(1):97-105 [1285215.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3376-8 [8012953.001]
  • [Cites] N Engl J Med. 1994 Jul 28;331(4):213-21 [8015568.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):747-51 [7989112.001]
  • [Cites] Arch Surg. 1995 Jan;130(1):9-14 [7802584.001]
  • [Cites] Gut. 1994 Nov;35(11):1627-31 [7828987.001]
  • [Cites] Cell. 1995 Jul 14;82(1):19-26 [7541721.001]
  • [Cites] Am J Surg. 1996 Jan;171(1):41-6 [8554149.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):491-7 [8814697.001]
  • [Cites] Int J Cancer. 1996 Jun 21;69(3):241-5 [8682594.001]
  • [Cites] Scand J Gastroenterol. 1997 Jan;32(1):62-9 [9018769.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3839-44 [9042267.001]
  • [Cites] Cancer J Sci Am. 1997 Sep-Oct;3(5):284-8 [9327152.001]
  • [Cites] J Pathol. 1997 Jul;182(3):318-24 [9349235.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1149-58 [9515799.001]
  • [Cites] Am J Surg. 1998 Mar;175(3):198-202 [9560119.001]
  • [Cites] J Natl Cancer Inst. 1998 May 6;90(9):675-84 [9586664.001]
  • [Cites] Gut. 1998 May;42(5):669-72 [9659162.001]
  • [Cites] Eur J Cancer. 1998 Mar;34(4):518-21 [9713302.001]
  • [Cites] Dis Colon Rectum. 1998 Aug;41(8):1033-49 [9715162.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):345-50 [9950438.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1375-81 [10334521.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2307-12 [10344734.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1805-13 [10362805.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):830-7 [10370622.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):883-90 [10370632.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] Ann Surg Oncol. 2004 Nov;11(11):977-82 [15525826.001]
  • [Cites] Mutat Res. 2004 Dec 21;568(2):275-82 [15542114.001]
  • [Cites] Oncol Rep. 2004 Dec;12(6):1221-5 [15547741.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):850-60 [15705883.001]
  • [Cites] Med Clin (Barc). 2005 Feb 5;124(4):121-5 [15713240.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):481-8 [15718248.001]
  • [Cites] Semin Oncol. 2005 Feb;32(1):52-60 [15726506.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] World J Gastroenterol. 2005 Apr 7;11(13):2022-5 [15800999.001]
  • [Cites] Drugs Today (Barc). 2005 Feb;41(2):107-27 [15821783.001]
  • [Cites] Oncologist. 2005 May;10(5):325-31 [15851790.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):279-86 [15863375.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1746-53 [15856045.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3536-44 [15908664.001]
  • [Cites] Ann Oncol. 2005 May;16 Suppl 4:iv44-49 [15923428.001]
  • [Cites] Ann Oncol. 2005 May;16 Suppl 4:iv50-55 [15923430.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):241-9 [15944796.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6063-9 [16024606.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):900-2 [11221878.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):299-304 [11208819.001]
  • [Cites] Eur J Surg Oncol. 2001 Feb;27(1):80-7 [11237496.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):358-63 [11289281.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):364-72; discussion 372-3 [11289282.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] Int J Cancer. 2001 May 20;95(3):162-7 [11307149.001]
  • [Cites] Dis Colon Rectum. 2001 Apr;44(4):549-57 [11330582.001]
  • [Cites] Int J Colorectal Dis. 2001 Apr;16(2):108-11 [11355316.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):6-11 [11391614.001]
  • [Cites] Cytogenet Cell Genet. 2001;92(3-4):177-81 [11435683.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):297-304 [11438476.001]
  • [Cites] Mol Pathol. 2001 Aug;54(4):206-14 [11477132.001]
  • [Cites] Eur J Surg Oncol. 2001 Aug;27(5):446-50 [11504513.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):692-6 [11531254.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):1129-35 [11549606.001]
  • [Cites] Curr Pharm Des. 2001 Nov;7(16):1581-94 [11562300.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1331-46 [11571750.001]
  • [Cites] J Pathol. 2001 Sep;195(2):191-6 [11592098.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15 [11597399.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13255-60 [11687624.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1435-43 [11745220.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Apr;16(2):331-45 [11969242.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1376-87 [11984524.001]
  • [Cites] Cancer Immunol Immunother. 2002 Jul;51(5):235-47 [12070710.001]
  • [Cites] Expert Rev Anticancer Ther. 2001 Aug;1(2):247-57 [12113030.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1438-46 [12196370.001]
  • [Cites] Cytometry. 2002 Aug 15;50(4):216-24 [12210601.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Nov;44(2):109-20 [12413630.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2258-64 [12441262.001]
  • [Cites] Clin Colorectal Cancer. 2001 Aug;1(2):110-6 [12445369.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):309-13 [12579264.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1608-14 [12670912.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Apr;46(1):33-57 [12672517.001]
  • [Cites] Folia Histochem Cytobiol. 2003;41(2):97-100 [12722796.001]
  • [Cites] Histopathology. 2003 Jul;43(1):40-7 [12823711.001]
  • [Cites] Cancer Immunol Immunother. 2003 Jul;52(7):423-8 [12695859.001]
  • [Cites] Ann Oncol. 2003 Jul;14(7):1026-38 [12853343.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2760-76 [12860956.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2898-903 [12912934.001]
  • [Cites] Surg Oncol. 2003 Nov;12(3):173-86 [12957621.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5209-12 [14500346.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5564-72 [14500396.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3729-36 [14551292.001]
  • [Cites] Int J Colorectal Dis. 2004 Jan;19(1):23-42 [12827409.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):191-5 [14734469.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):39-45 [14758132.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):242-6 [14760116.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):493-501 [14968119.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):469-75 [15048750.001]
  • [Cites] Jpn J Clin Oncol. 2004 Feb;34(2):90-8 [15067103.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Int J Colorectal Dis. 2004 Jul;19(4):380-6 [14634776.001]
  • [Cites] Clin Colorectal Cancer. 2004 May;4(1):38-45 [15207019.001]
  • [Cites] Hum Pathol. 2004 Jul;35(7):808-16 [15257543.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):688-9; author reply 689-90 [15300610.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2519-30 [15330208.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:791-801 [15338774.001]
  • [Cites] Fam Cancer. 2004;3(2):85-91 [15340258.001]
  • [Cites] Curr Treat Options Oncol. 2004 Oct;5(5):393-403 [15341677.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13(19):2303-11 [15294875.001]
  • [Cites] J Cell Sci. 1999 Nov;112 ( Pt 22):3943-54 [10547355.001]
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] Eur J Cancer. 2000 May;36(8):1008-15 [10885605.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3A):1695-701 [10928094.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3560-4 [10999744.001]
  • [Cites] Gastroenterology. 2000 Oct;119(4):921-8 [11040179.001]
  • [Cites] Am J Gastroenterol. 2000 Oct;95(10):2953-7 [11051374.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7 [11097226.001]
  • [Cites] Hum Pathol. 2000 Dec;31(12):1506-14 [11150376.001]
  • [Cites] Gut. 2001 Mar;48(3):360-6 [11171826.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):827-30 [11221863.001]
  • (PMID = 20584808.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3228001
  •  go-up   go-down


55. Bond MR, Zhang H, Vu PD, Kohler JJ: Photocrosslinking of glycoconjugates using metabolically incorporated diazirine-containing sugars. Nat Protoc; 2009;4(7):1044-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transient interactions among glycoconjugates underlie developmental, immunological and metastatic recognition.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DIAZOMETHANE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536272.001).
  • [ISSN] 1750-2799
  • [Journal-full-title] Nature protocols
  • [ISO-abbreviation] Nat Protoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / Glycoconjugates; 0 / Sialic Acids; 60A625P70P / Diazomethane
  •  go-up   go-down


56. Lei KF, Wang YF, Zhu XQ, Lu PC, Sun BS, Jia HL, Ren N, Ye QH, Sun HC, Wang L, Tang ZY, Qin LX: Identification of MSRA gene on chromosome 8p as a candidate metastasis suppressor for human hepatitis B virus-positive hepatocellular carcinoma. BMC Cancer; 2007;7:172
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of MSRA gene on chromosome 8p as a candidate metastasis suppressor for human hepatitis B virus-positive hepatocellular carcinoma.
  • BACKGROUND: The prognosis of patients with hepatocellular carcinoma (HCC) still remains very dismal, which is mainly due to metastasis.
  • In this study, we aimed to identify the candidate metastatic suppressor gene on chromosome 8p.
  • Real-time PCR and Western blotting confirmed that the mRNA and protein expression levels of MSRA were significantly decreased in HCC with metastasis compared with those without metastasis (p < 0.001), and MSRA mRNA level in HCCLM6 cells (with high metastatic potential) was also much lower than that of other HCC cell lines.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Chromosomes, Human, Pair 8. Genes, Tumor Suppressor. Hepatitis B virus / isolation & purification. Liver Neoplasms / genetics. Neoplasm Metastasis / prevention & control. Oxidoreductases / genetics

  • Genetic Alliance. consumer health - Chromosome 8p.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(5):814-21 [10555751.001]
  • [Cites] Nat Biotechnol. 2006 Sep;24(9):1140-50 [16964228.001]
  • [Cites] Br J Cancer. 2000 Jan;82(1):65-73 [10638968.001]
  • [Cites] Anal Biochem. 2000 Feb 15;278(2):175-84 [10660460.001]
  • [Cites] Clin Exp Metastasis. 1999;17(6):471-9 [10763912.001]
  • [Cites] Surgery. 2000 Jun;127(6):603-8 [10840353.001]
  • [Cites] Carcinogenesis. 2000 Sep;21(9):1721-6 [10964104.001]
  • [Cites] Hepatology. 2000 Oct;32(4 Pt 1):721-7 [11003615.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1717-30 [11058615.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Jul;31(3):221-7 [11391792.001]
  • [Cites] J Hepatol. 2001 Jun;34(6):840-9 [11451167.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Aug;127(8):482-8 [11501747.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Oct 15;130(2):127-32 [11675133.001]
  • [Cites] Curr Opin Oncol. 2002 Jan;14(1):65-72 [11790983.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):367-70 [11809681.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S153-8 [11821803.001]
  • [Cites] Cancer Lett. 2002 Apr 25;178(2):199-207 [11867205.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1438-45 [12424114.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Nat Med. 2003 Apr;9(4):416-23 [12640447.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 May;129(5):279-86 [12734753.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8199-204 [12824466.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1005-10 [14651971.001]
  • [Cites] Br J Cancer. 2004 Feb 23;90(4):752-5 [14970848.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):706-17 [14991762.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9654-9 [15199188.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Aug;130(8):460-8 [15146329.001]
  • [Cites] Endocrinology. 2004 Aug;145(8):3769-77 [15131018.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5697-702 [15184884.001]
  • [Cites] J Natl Cancer Inst. 1995 Nov 1;87(21):1588-92 [7563201.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2095-9 [8700890.001]
  • [Cites] Clin Exp Metastasis. 1996 Nov;14(6):520-9 [8970582.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2196-9 [9605766.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):418-23 [9699536.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):447-52 [10023714.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3928-33 [10097140.001]
  • [Cites] Genes Chromosomes Cancer. 1999 May;25(1):1-5 [10221333.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):267-74 [10393858.001]
  • [Cites] FEBS Lett. 1999 Jul 30;456(1):17-21 [10452521.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1351-3 [10451432.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):253-7 [10502324.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Dec;130(12):719-27 [15340842.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1207-12 [15735004.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] N Engl J Med. 2005 Sep 15;353(11):1124-34 [16162883.001]
  • [Cites] J Virol. 2005 Nov;79(22):14392-403 [16254373.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):229-35 [16432356.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1832-40 [16261160.001]
  • [Cites] BMC Mol Biol. 2006;7:11 [16542431.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5662-5 [10582679.001]
  • (PMID = 17784942.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.- / Oxidoreductases; EC 1.8.4.- / Methionine Sulfoxide Reductases; EC 1.8.4.11 / methionine sulfoxide reductase
  • [Other-IDs] NLM/ PMC2000900
  •  go-up   go-down


57. Valero Fuentealba G: [Antegrade ejaculation after modified lumboaortic laparoscopic lymphadenectomy]. Arch Esp Urol; 2008 May;61(4):517-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Testicular cancer affects young and fertile patients.
  • The management of this cancer in stage I includes: watchful waiting, chemotherapy and retroperitoneal lymph node dissection (RPLND).
  • The objective of this work is to show the conservation of antegrade ejaculation and some surgical anal cortical features of the modified laparoscopic RPLND.
  • Metastatic lymph node involvement was found in 29% of the patients 17/24).

  • MedlinePlus Health Information. consumer health - Sexual Problems in Men.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592770.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


58. Blonder J, Johann DJ, Veenstra TD, Xiao Z, Emmert-Buck MR, Ziegler RG, Rodriguez-Canales J, Hanson JA, Xu X: Quantitation of steroid hormones in thin fresh frozen tissue sections. Anal Chem; 2008 Nov 15;80(22):8845-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, a liquid chromatography-tandem mass spectrometry method that utilizes selected reaction monitoring was used to measure the absolute quantity of estrogens and estrogen metabolites and testosterone in 8-microm tissue sections obtained from a fresh frozen lymph node tumor infiltrated by metastatic breast carcinoma.

  • MedlinePlus Health Information. consumer health - Hormones.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937426.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 0 / Hormones; 0 / Steroids; 3XMK78S47O / Testosterone
  •  go-up   go-down


59. Spugnini EP, Dotsinsky I, Mudrov N, Cardosi G, Citro G, D'Avino A, Baldi A: Biphasic pulses enhance bleomycin efficacy in a spontaneous canine perianal tumors model. J Exp Clin Cancer Res; 2007 Dec;26(4):483-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Perianal tumors (adenoma and carcinoma of the hepatoid glands) are frequently reported in veterinary literature.
  • They are locally aggressive tumors with a low tendency to metastatic spread.
  • Twelve canine patients, eight with adenoma and four with carcinoma of the perianal glands, entered the study and received two sessions of ECT under sedation.
  • [MeSH-major] Anal Gland Neoplasms / drug therapy. Antibiotics, Antineoplastic / analysis. Bleomycin / analysis. Dog Diseases / drug therapy. Electrochemotherapy / methods

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365542.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


60. Stuelten CH, Busch JI, Tang B, Flanders KC, Oshima A, Sutton E, Karpova TS, Roberts AB, Wakefield LM, Niederhuber JE: Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One; 2010;5(3):e9832
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer.
  • Carcinoma are complex societies of mutually interacting cells in which there is a progressive failure of normal homeostatic mechanisms, causing the parenchymal component to expand inappropriately and ultimately to disseminate to distant sites.
  • When a cancer cell metastasizes, it first will be exposed to cancer associated fibroblasts in the immediate tumor microenvironment and then to normal fibroblasts as it traverses the underlying connective tissue towards the bloodstream.
  • Here, we report a role for normal stroma fibroblasts in the progression of invasive tumors to metastatic tumors.
  • Using a coculture system of human metastatic breast cancer cells (MCF10CA1a) and normal murine dermal fibroblasts, we found that medium conditioned by cocultures of the two cell types (CoCM) increased migration and scattering of MCF10CA1a cells in vitro, whereas medium conditioned by homotypic cultures had little effect.
  • Transient treatment of MCF10CA1a cells with CoCM in vitro accelerated tumor growth at orthotopic sites in vivo, and resulted in an expanded pattern of metastatic engraftment.
  • In conclusion, these results demonstrate that transient interactions between tumor cells and normal fibroblasts can modify the acellular component of the local microenvironment such that it induces long-lasting increases in tumorigenicity and alters the metastatic pattern of the cancer cells in vivo.
  • TGF-beta appears to be a key player in this process, providing further rationale for the development of anti-cancer therapeutics that target the TGF-beta pathway.